<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1109234176
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ABILIFY MAINTENA 400 mg Powder And Solvent For Prolonged-Release
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ARIPIPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for prolonged-release suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1188.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="OTSUKA PHARMACEUTICAL CO., LTD" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            OTSUKA PHARMACEUTICAL CO., LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            H. LUNDBECK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AX12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Abilify Maintena contains the active substance aripiprazole and belongs to a group of medicines called<br />antipsychotics. Abilify Maintena helps to correct a chemical imbalance in the brain which may cause<br />schizophrenia and Bipolar I Disorder.</p><p><br />Schizophrenia is a disease characterised by symptoms such as:<br /> hallucinations: hearing, seeing or sensing things which are not there<br /> suspiciousness, mistaken beliefs and<br /> incoherent speech and behaviour and emotional flatness.</p><p><br />People with this condition may also feel depressed, guilty, anxious or tense. Abilify Maintena is<br />intended for adult patients with schizophrenia.</p><p><br />Bipolar I disorder is a condition with symptoms such as:<br /> having excessive amounts of energy,<br /> needing much less sleep than usual,<br /> talking very quickly with racing ideas and<br /> sometimes severe irritability.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Abilify Maintena:<br />- if you are allergic to aripiprazole or any of the other ingredients of this medicine (listed in<br />section 6).<br />Warnings and precautions<br />Talk to your doctor or nurse before you are given Abilify Maintena.<br />Suicidal thoughts and behaviours have been reported during aripiprazole treatment. Tell your doctor<br />immediately if you are having any thoughts or feelings about hurting yourself.<br />Before treatment with Abilify Maintena, tell your doctor if you suffer from<br /> high blood sugar (characterised by symptoms such as excessive thirst, passing of large amounts of<br />urine, increase in appetite and feeling weak) or family history of diabetes<br /> fits (seizures) since your doctor may want to monitor you more closely<br /> involuntary, irregular muscle movements, especially in the face<br /> cardiovascular diseases (diseases of the heart and circulation), family history of cardiovascular<br />disease, stroke or &quot;mini&quot; stroke, abnormal blood pressure<br /> blood clots, or family history of blood clots, as antipsychotics have been associated with<br />formation of blood clots<br /> past experience with excessive gambling<br /> severe liver problems.<br />If you notice you are gaining weight, develop unusual movements, experience sleepiness that<br />interferes with normal daily activities, any difficulty in swallowing or have allergic symptoms, please<br />talk to your doctor immediately.<br />Tell your doctor if you or your family/carer notices that you are developing urges or cravings to<br />behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry<br />out certain activities that could harm yourself or others. These are called impulse control disorders and<br />can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high<br />sex drive or preoccupation with an increase in sexual thoughts or feelings.<br />Your doctor may need to adjust or stop your dose.<br />Aripiprazole may cause sleepiness, fall in blood pressure when standing up, dizziness and changes in<br />your ability to move and balance, which may lead to falls. Caution should be taken, particularly if you<br />are an elderly patient or have some debility.<br />Children and adolescents<br />Do not use this medicine in children and adolescents under 18 years of age. It is not known if it is safe<br />and effective in these patients.<br />Other medicines and Abilify Maintena<br />Tell your doctor if you are taking, have recently taken or plan to take any other medicines, including<br />medicines obtained without a prescription.</p><p>&nbsp;</p><p>Blood pressure-lowering medicines: Abilify Maintena may increase the effect of medicines used to<br />lower the blood pressure. Be sure to tell your doctor if you take a medicine to keep your blood<br />pressure under control.<br />Receiving Abilify Maintena with some medicines may mean the doctor will need to change your dose<br />of Abilify Maintena or the other medicines. It is especially important to mention the following to your<br />doctor:<br /> medicines to correct heart rhythm (such as quinidine, amiodarone, flecainide)<br /> antidepressants or herbal remedy used to treat depression and anxiety (such as fluoxetine,<br />paroxetine, venlafaxine, St. John&#39;s Wort)<br /> antifungal medicines (such as ketoconazole, itraconazole)<br /> certain medicines to treat HIV infection (such as efavirenz, nevirapine, an protease inhibitors e.g.<br />indinavir, ritonavir)<br /> anticonvulsants used to treat epilepsy (such as carbamazepine, phenytoin, phenobarbital)<br /> certain antibiotics used to treat tuberculosis (rifabutin, rifampicin)<br />These medicines may increase the risk of side effects or reduce the effect of Abilify Maintena; if you<br />get any unusual symptom taking any of these medicines together with Abilify Maintena, you should<br />see your doctor.<br />Medicines that increase the level of serotonin are typically used in conditions including depression,<br />generalised anxiety disorder, obsessive-compulsive disorder (OCD) and social phobia as well as<br />migraine and pain:<br /> triptans, tramadol and tryptophan used for conditions including depression, generalised anxiety<br />disorder, obsessive compulsive disorder (OCD) and social phobia as well as migraine and pain<br /> SSRI s (such as paroxetine and fluoxetine) used for depression, OCD, panic and anxiety<br /> other anti-depressants (such as venlafaxine and tryptophan) used in major depression<br /> tricyclic&rsquo;s (such as clomipramine and amitriptyline) used for depressive illness<br /> St John&rsquo;s Wort (Hypericum perforatum) used as a herbal remedy for mild depression<br /> pain killers (such as tramadol and pethidine) used for pain relief<br /> triptans (such as sumatriptan and zolmitripitan) used for treating migraine<br />These medicines may increase the risk of side effects; if you get any unusual symptom taking any of<br />these medicines together with Abilify Maintena, you should see your doctor.<br />Abilify Maintena with alcohol<br />Alcohol should be avoided.<br />Pregnancy, breast-feeding and fertility<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask<br />your doctor for advice before receiving this medicine.<br />You should not be given Abilify Maintena if you are pregnant unless you have discussed this with<br />your doctor. Be sure to tell your doctor immediately if you are pregnant, think you may be pregnant,<br />or if you are planning to become pregnant.<br /><br />The following symptoms may occur in new-born babies, of mothers that have received Abilify<br />Maintena in the last trimester (last three months of their pregnancy):<br />shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in<br />feeding.<br />If your baby develops any of these symptoms you need to contact your doctor.<br />If you are receiving Abilify Maintena, your doctor will discuss with you whether you should breastfeed<br />considering the benefit to you of your therapy and the benefit to your baby of breast-feeding. You<br />should not do both. Talk to your doctor about the best way to feed your baby if you are receiving<br />Abilify Maintena.<br />Driving and using machines<br />Dizziness and vision problems may occur during treatment with this medicine (see section 4). This<br />should be considered in cases where full alertness is required, e.g., when driving a car or handling<br />machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Abilify Maintena comes as a powder which your doctor or nurse will make into a suspension. Your<br />doctor will give it to you as a single injection into the gluteal or deltoid muscle (buttock or shoulder)<br />every month. You may feel a little pain during the injection. Your doctor will alternate the injections<br />between your right and left side. The injections will not be given intravenously.<br />Your doctor will decide on the dose of Abilify Maintena that is right for you. The recommended and<br />starting dose is 400 mg unless your doctor decided to give you a lower starting or follow up dose (300<br />mg, 200 mg or 160 mg). There are two ways to start Abilify Maintena, your doctor<br />will decide which way is right for you.<br />&bull; If you are given one injection of Abilify Maintena on your first day the treatment with your current antipsychotic by mouth is continued for 14 days after the first injection.<br />&bull; If you are given two injections of Abilify Maintena on your first day, you will also take one tablet of aripiprazole by mouth at this visit.&nbsp;After that, treatment is given with<br />injections of Abilify Maintena unless your doctor tells you otherwise.<br />If you are given more Abilify Maintena than you need<br />This medicine will be given to you under medical supervision; it is therefore unlikely that you will be<br />given too much. If you see more than one doctor, be sure to tell them that you are receiving Abilify<br />Maintena.<br />Patients who have been given too much aripiprazole have experienced the following symptoms:<br /> rapid heart beat, agitation/aggressiveness, problems with speech.<br /> unusual movements (especially of the face or tongue) and reduced level of consciousness.<br />Other symptoms may include:<br /> acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating,<br /> muscle stiffness, and drowsiness or sleepiness, slower breathing, choking, high or low blood<br />pressure, abnormal rhythms of the heart.<br />Contact your doctor or hospital immediately if you experience any of the above.<br />If you miss an injection of Abilify Maintena<br />It is important not to miss your scheduled dose. You should be given an injection every month but not<br />before the 26 days has passed from the last injection. If you miss an injection, you should contact your<br /><br />doctor to arrange your next injection as soon as you can. If you have any further questions on the use<br />of this medicine, ask your doctor or nurse.<br />If you stop receiving Abilify Maintena<br />Do not stop your treatment just because you feel better. It is important that you carry on receiving<br />Abilify Maintena for as long as your doctor has told you to.<br />If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor immediately if you have any of the following serious side effects:</p><p>&bull;&nbsp;&nbsp; &nbsp;a combination of any of these symptoms: excessive sleepiness, dizziness, confusion, disorientation, difficulty talking, difficulty walking, muscle stiffness or shaking, fever, weakness, irritability, aggression, anxiety, increase in blood pressure, or seizures that can lead to unconsciousness.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;unusual movement mainly of the face or tongue, since your doctor may want to lower your dose.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;if you have symptoms such as swelling, pain, and redness in the leg, because this may mean you have a blood clot, which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. If you notice any of these symptoms seek medical advice immediately.<br />&bull;&nbsp;&nbsp; &nbsp;a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness since this may be a sign of a condition called neuroleptic malignant syndrome (NMS).<br />&bull;&nbsp;&nbsp; &nbsp;thirstiness more than usual, need to urinate more than usual, feel very hungry, feel weak or tired, feel sick , feel confused or your breath smells fruity, since this may be a sign of diabetes.</p><p>The side effects listed below may also occur after receiving Abilify Maintena.</p><p>Common side effects (may affect up to 1 in 10 people):</p><p>&bull;&nbsp;&nbsp; &nbsp;weight gain, weight loss<br />&bull;&nbsp;&nbsp; &nbsp;feeling anxious, difficulty sleeping (insomnia)<br />&bull;&nbsp;&nbsp; &nbsp;feeling restless and unable to keep still, difficulty sitting still, trembling, uncontrollable twitching, jerking or writhing movements, , restless legs<br />&bull;&nbsp;&nbsp; &nbsp;changes in your level of alertness, drowsiness<br />&bull;&nbsp;&nbsp; &nbsp;muscle movements that you cannot control such as grimacing, lip-smacking and tongue movements. They usually affect the face and mouth first but can affect other parts of the body. These could be signs of a condition called &ldquo;tardive dyskinesia&rdquo;.<br />&bull;&nbsp;&nbsp; &nbsp;parkinsonism; this is a medical term that includes several symptoms such as muscle stiffness, jerks when bending the limbs, slow or impaired body movements, no expression on the face, muscle tightness, shuffling, hurried steps and lack of normal arm movements when walking<br />&bull;&nbsp;&nbsp; &nbsp;jerky resistance to passive movement as muscles tense and relax, abnormally increased muscle tone, muscle stiffness, slow body movement<br />&bull;&nbsp;&nbsp; &nbsp;dizziness, headache<br />&bull;&nbsp;&nbsp; &nbsp;dry mouth<br />&bull;&nbsp;&nbsp; &nbsp;pain at the injection site, hardening of the skin at the injection site<br />&bull;&nbsp;&nbsp; &nbsp;weakness, loss of strength or extreme tiredness<br />&bull;&nbsp;&nbsp; &nbsp;high blood levels of the enzyme creatine phosphokinase&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><p>&bull;&nbsp;&nbsp; &nbsp;decreased or increased appetite, distortion of the senses of taste and smell<br />&bull;&nbsp;&nbsp; &nbsp;low level of a specific type of white blood cells (neutropenia), low haemoglobin or red blood cell count, low level of blood platelets<br />&bull;&nbsp;&nbsp; &nbsp;allergic reactions (hypersensitivity)<br />&bull;&nbsp;&nbsp; &nbsp;decreased or increased blood levels of the hormone prolactin<br />&bull;&nbsp;&nbsp; &nbsp;high blood sugar, decreased blood sugar&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;increased blood fats such as high cholesterol, high triglycerides and also low level of cholesterol and low level of triglycerides<br />&bull;&nbsp;&nbsp; &nbsp;increased levels of insulin, a hormone regulating blood sugar levels<br />&bull;&nbsp;&nbsp; &nbsp;thoughts about suicide<br />&bull;&nbsp;&nbsp; &nbsp;mental disorder characterized by defective or lost contact with reality, hallucination, delusion<br />&bull;&nbsp;&nbsp; &nbsp;increased sexual activity, decreased sexual activity<br />&bull;&nbsp;&nbsp; &nbsp;panic reaction, depression, affect lability, state of indifference with lack of emotion, feelings of emotional and mental discomfort, altered mood<br />&bull;&nbsp;&nbsp; &nbsp;sleep disorder<br />&bull;&nbsp;&nbsp; &nbsp;grinding of teeth or clenching of the jaw<br />&bull;&nbsp;&nbsp; &nbsp;hiccups<br />&bull;&nbsp;&nbsp; &nbsp;fixation of the eyeballs in one position, blurred vision, eye pain, double vision<br />&bull;&nbsp;&nbsp; &nbsp;abnormal heart beat, slow or fast heart rate, abnormal electrical conduction of the heart, abnormal reading (ECG) of the heart<br />&bull;&nbsp;&nbsp; &nbsp;dizziness when getting up from a lying or sitting position due to a drop in blood pressure, high blood pressure&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;cough&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;upset stomach, indigestion, drooling, more saliva in mouth than normal, vomiting, nausea, diarrhoea, constipation, stomach ache or discomfort, frequent bowel movement&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;abnormal liver blood values&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;abnormal hair loss&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;acne, skin condition of the face where the nose and cheeks are unusually red, eczema, skin hardening<br />&bull;&nbsp;&nbsp; &nbsp;muscle rigidity, muscle spasms, muscle twitching, muscle tightness, mucle pain (myalgia), pain in extremity, gait disturbance,joint pain ( arthralgia), back pain, decreased &nbsp;range of motion of joints, stiff neck, limited opening of mouth<br />&bull;&nbsp;&nbsp; &nbsp;kidney stones, sugar (glucose) in urine&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;enlargement of breast in men, breast tenderness, vaginal dryness<br />&bull;&nbsp;&nbsp; &nbsp;loss of strength&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;chest discomfort&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;injection site reactions such as redness, swelling discomfort and injection site itching&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;increased waist circumference&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;eye sensitivity to light<br />&bull;&nbsp;&nbsp; &nbsp;sleepwalking (this adverse effect has been reported in clinical trials with oral aripiprazole and not Abilify Maintena)</p><p>The following side effects have been reported since the marketing of oral aripiprazole but the frequency for them to occur is not known:&nbsp;</p><p>&bull;&nbsp;&nbsp; &nbsp;low levels of white blood cells<br />&bull;&nbsp;&nbsp; &nbsp;unusual heartbeat, sudden unexplained death, heart attack&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;allergic reaction (e.g. swelling in the mouth, tongue, face and throat, itching, hives), rash<br />&bull;&nbsp;&nbsp; &nbsp;ketoacidosis (ketones in the blood and urine) or coma, low sodium level in the blood&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;loss of appetite (anorexia), difficulty in swallowing<br />&bull;&nbsp;&nbsp; &nbsp;aggression<br />&bull;&nbsp;&nbsp; &nbsp;nervousness, suicide attempt and suicide; speech disorder, seizure, serotonin syndrome (a reaction which may cause feelings of great happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles), combination of fever, muscle stiffness, faster breathing, sweating, reduced consciousness and sudden changes in blood pressure and heart rate (neuroleptic malignant syndrome)&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;fainting, spasm of the muscles around the voice box, accidental inhalation of food with risk of pneumonia (lung infection), inflammation of the pancreas<br />&bull;&nbsp;&nbsp; &nbsp;liver failure, inflammation of the liver, yellowing of the skin and white part of eyes, sensitivity to light, excessive sweating, stiffness or cramps, muscle pain, weakness&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;involuntary loss of urine (incontinence), difficulty in passing urine&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;prolonged and/or painful erection&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;difficulty controlling core body temperature or overheating, chest pain, and swelling of hands, ankles or feet<br />&bull;&nbsp;&nbsp; &nbsp;Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:<br />-&nbsp;&nbsp; &nbsp;strong impulse to gamble excessively despite serious personal or family conse-quences<br />-&nbsp;&nbsp; &nbsp;altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive<br />-&nbsp;&nbsp; &nbsp;uncontrollable excessive shopping<br />-&nbsp;&nbsp; &nbsp;binge eating (eating large amounts of food in a short time period) or compulsive eat-ing (eating more food than normal and more than is needed to satisfy your hunger)<br />- &nbsp;&nbsp; &nbsp;a tendency to wander away<br />&bull;&nbsp;&nbsp; &nbsp;serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symp-toms (DRESS). DRESS appears initially as flu-like symptoms with a rash on the face and then with an extended rash, high temperature, enlarged lymph nodes, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosino-philia).</p><p>Tell your doctor if you experience any of these behaviours; he/she will discuss ways of managing orreducing the symptoms.</p><p>Reporting of side effects<br />If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect(s):&nbsp;</p><p>Saudi Arabia:&nbsp;<br />The National Pharmacovigilance Centre (NPC):<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p>Other GCC States:<br />- Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to<br />the last day of that month.<br />Do not store above 30 &ordm;C.<br />Do not freeze.<br /><br />The reconstituted suspension should be used immediately but may be stored below 25&deg;C for up to<br />4 hours in the vial. Do not store the reconstituted suspension in the syringe.<br />Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines<br />you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is aripiprazole.<br />Each vial contains 400 mg aripiprazole.<br />After reconstitution each ml of suspension contains 200 mg aripiprazole.<br />- The other ingredients are<br />Powder<br />Carmellose sodium, mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide<br />Solvent<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Abilify Maintena is a powder and solvent for prolonged-release suspension for injection.
Abilify Maintena comes as a white to off-white powder in a clear glass vial. Your doctor or nurse will
make it into a suspension that will be given as an injection using the vial of solvent for Abilify
Maintena that comes as a clear solution in a clear glass vial.
Each single pack containing one vial of powder and one vial of solvent.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder<br />H. Lundbeck A/S<br />Ottiliavej 9, 2500 Valby<br />Denmark<br />Manufacturer<br />H. Lundbeck A/S<br />Ottiliavej 9, 2500 Valby<br />Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in May 2023.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي عقار أبيليفاي مينتينا على المادة الفعالة أريبيبرازول التي تنتمي إلى مجموعة من الأدوية تسُمى مُضادات الذهان.</p><p>يساعد أبيليفاي مينتينا على تصحيح الخلل الكيميائي الذي قد يسبب الفصام و الاضطراب ثنائي القطب.</p><p>مرض الفصام هو مرض يتميز بأعراض، مثل:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سماع أو رؤية أشياء غير موجودة أو الإحساس بها</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الريبة، الاعتقادات الخاطئة</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلام غير مترابط، جمود عاطفي وسلوكي</p><p>&nbsp;</p><p>قد يشعر أيضا الأشخاص المصابون بهذه الحالة بالاكتئاب أو بالذنب أو بالقلق أو بالتوتر.<em> </em></p><p><em>&nbsp;</em></p><p>يُعُد عقار أبيليفاي مينتينا مخصَّص للمرضى البالغين المصابين بالفصام.<em> </em></p><p><em>&nbsp;</em></p><p>الاضطراب ثنائي القطب هو حالة لها أعراض مثل:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحساس بطاقة مفرطة</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحاجة الى وقت من النوم أقل من المعتاد</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التحدث بسرعة كبيرة مع تسارع في الأفكار</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخرش شديد في الجلد، في بعض الأحيان</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستخدم عقار أبيليفاي مينتينا في الحالات التالية:</strong><em> </em></p><p><em>&nbsp;</em></p><p>&nbsp;إذا كنت تعاني من حساسية تجاه أريبيبرازول أو تجاه أي من المكونات الأخرى لهذا الدَّواء (المدرجة في القسم &quot;6&quot;).<em> </em></p><p><strong>&nbsp;</strong></p><p><strong>تحذيرات واحتياطات </strong><em>&nbsp;</em></p><p>تحدَّث إلى الطبيب أو الممرض(ة)الخاص بك قبل تناوُل عقار أبيليفاي مينتينا.<em> </em></p><p>لقد تم الإبلاغ عن حالات أفكار وسلوكيات انتحارية أثناء العلاج باستخدام أريبيبرازول. يجب عليكِ أن تخبر طبيبكِ فورً ا إذا كانت تراودك أيةَّ أفكار أو احساس بأنك تريد أن تؤذي نفسك.<em> </em></p><p><em>&nbsp;</em></p><p>قبل العلاج باستخدام عقار أبيليفاي مينتينا، أخبر طبيبك إذا كنت تعاني مما يلي:<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع السكر بالدَّ م (تتميزَّ بأعراض مثل العطش المفرط، وإخراج كميات كبيرة من البول، وزيادة الشهية والشعور بالضعف) أو تاريخ عائلي سابق من الإصابة بمرض السُّكَّرِي.<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات صرع (نوبات تشنجية) حيث أنه في هذه الحالة قد يرغب طبيبك في مراقبتك بشكل أكثر دقة.<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات عضلية لا إرادية غير منتظمة، لا سيما في الوجه.<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض القلب والأوعية الدموية (أمراض القلب والدورة الدموية)، والتاريخ العائلي لأمراض القلب والأوعية الدموية والسكتة الدماغية أو السكتة الدماغية &quot;الصغرى&quot;، وضغط الدم غير الطبيعي.<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بجلطات الدَّم، أو تاريخ عائلي سابق من الإصابة بالجلطات الدموية حيث أ نَّه قد تم الربط بين مضادات الذهان وتكوُّ ن الجلطات الدموية.<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إدمان القمار في الماضي.<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بمشاكل شديدة بالكبد.<em> </em></p><p>إذا لاحظت زيادة في الوزن أو الإصابة بحركات غير معتادة أو التعرُّض لنعاس يتداخل مع الأنشطة اليومية العادية أو أ ي صعوبة في البلع أو أعراض الحساسية، فيُرُجى اخبار طبيبك فورً ا.<em> </em></p><p>&nbsp;</p><p>أخبر طبيبك اذا لاحظت أنت أو عائلتك/ مقدم الرعاية أنك تشعر بزيادة الحث أو الرغبة الشديدة في التصرف بطرق غير اعتيادية بالنسبة لك و لا تستطيع مقاومة الاندفاع، أو القيادة أو الإغراء للقيام بأنشطة معينة يمكن أن تؤذي نفسك أو الآخرين. هذه تسمى اضطرابات السيطرة على الإندفاع، و يمكن أن تشمل السلوكيات مثل المقامرة الإدمانية، الأكل المفرط أو الإنفاق، الشعور بالدافع الجنسي بشكل غير طبيعي أو الإنشغال بزيادة الأفكار أو المشاعر الجنسية.</p><p>قد يحتاج طبيبك إلى ضبط الجرعة أو إيقافها.</p><p>السقطات</p><p>أريبيبرازول قد يسبب النعاس، انخفاض ضغط الدم الوضعي، عدم الاستقرار الحركي والحسي، مما قد يؤدي إلى السقوط. يجب توخي الحذر عند علاج المرضى المعرضين لمخاطر أكبر، ويجب النظر في البدء بجرعة أقل (مثل المرضى المسنين أو المصابين بالوهن).</p><p><em>&nbsp;</em></p><p><strong>الأطفال والمراهقون</strong><em> </em></p><p><em>&nbsp;</em></p><p>لا يستخدم هذا الدَّواء للأطفال والمراهقين أقل من 18 عام، لأنه غير معروف عما إذا كان هذا الدَّواء آمناً وفعالًا لهؤلاء المرضى أم لا.<em> </em></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><strong>تناوُل عقار أبيليفاي مينتينا مع أدوية أخرى</strong><em> </em></p><p><em>&nbsp;</em></p><p>يُرُجى إبلاغ الطبيب أو الصيدلي أو الممرض(ة) الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أيَّة أدوية أخرى، بما في ذلك الأدوية التي حصلت عليها دون وصفة طبية.<em> </em></p><p><em>&nbsp;</em></p><p>الأدوية الخافضة لضغط الدَّم: قد يؤدي عقار أبيليفاي مينتينا إلى زيادة تأثير الأدوية الخافضة لضغط الدَّم. تأكد من إخبار الطبيب إذا كنت تتناول دواء لضبط ضغط الدَّم لديك.<em> </em></p><p><em>&nbsp;</em></p><p>إنَّ تناوُل عقار أبيليفاي مينتينا مع بعض الأدوية يعني أن الطبيب قد يحتاج إلى تغيير جرعتك من عقار أبيليفاي مينتينا أو الأدوية الأخرى. يُعُد من الهام للغاية أن تخبر طبيبك بالآتي:<em> </em></p><p><em>&nbsp;</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة في تصحيح معدل النظم القلبي (مثل كينيدين، أميودارون، فليكانيد).<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب أو العلاجات المحتوية على أعشاب والتي تستخدم في علاج الاكتئاب والقلق<strong> (</strong>مثل فلوكسيتين ،باروكسيتين، فينلافاكسين، عشبة سانت جونز).<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للفطريات (مثل كيتوكونازول، إتراكونازول).<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة لعلاج عدوى فيروس نقص المناعة المكتسبة &quot; <em>HIV</em> <em>&ldquo;</em>(مثل إيفافيرينز ونيفيرابين، أحد مثبطات إنزيم البروتياز مثل إندينافير وريتونافير).<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج الصرع (مثل كَرْبامازِيبين, فينيتوين, فينوباربيتال).<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية المستخدمة لعلاج السل (ريفابوتين، ريفامبيسين).<strong><em> </em></strong></p><p><em>&nbsp;</em></p><p>قد ترفع هذه الأدوية من خطر حدوث الآثار الجانبية أو تحد من تأثيرات أبيليفاي مينتينا؛ يرجى مراجعة طبيبك إذا أصبت بأي أعراض غير معتادة أثناء تناوُل عقار أبيليفاي مينتينا مع هذه الأدوية.<em> </em></p><p><em>&nbsp;</em></p><p>الأدوية التي ترفع مستويات السيروتونين والتي تستخدم عادةً في علاج حالات تشمل الاكتئاب، اضطراب القلق المعمم، اضطراب الوسواس القهري، الرهاب الاجتماعي وكذلك الصداع النصفي والألم. <em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>التريبتانات وترامادول وتريبتوفان الذي يُسُتخدم عادة في علاج حالات تشمل الاكتئاب، اضطراب القلق المعمم، اضطراب الوسواس القهري، الرهاب الاجتماعي وكذلك الصداع النصفي والألم.<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات إعادة امتصاص السيروتونين الانتقائية (مثل باروكسيتين وفلوكسيتين) المستخدمة لعلاج الاكتئاب، اضطراب الوسواس القهري، نوبات الهلع والقلق.<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب الأخرى (مثل فينلافاكسين وتريبتوفان) المستخدمة لعلاج اضطراب الاكتئاب الرئيسي.<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقاقير ثلاثية الحلقات (مثل كلوميبرامين و أميتريبيتيلين) المستخدمة لعلاج الاكتئاب.<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز (هايبريكوم برفوراتام) المستخدمة كدواء عشبي لعلاج الاكتئاب الخفيف.<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مسكنات الألم (مثل ترامادول و بيثيدين) المستخدمة لعلاج الألم.<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التريبتانات (مثل سوماتريبتان و زولميتريبتان) المستخدمة لعلاج الصداع النصفي.<em> </em></p><p>قد ترفع هذه الأدوية من خطر حدوث الآثار الجانبية؛ يرُجى مراجعة طبيبك في حالة الإصابة بأي أعراض غير معتادة أثناء تناوُل عقار أبيليفاي مينتينا مع أ ي من هذه الأدوية.</p><p><em>&nbsp;</em></p><p><strong>تناوُل أبيليفاي مينتينا مع الكحوليات</strong></p><p>يجب تجنب&nbsp;تناوُل الكحوليات.<em> </em></p><p><em>&nbsp;</em></p><p><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong><em> </em></p><p>إذا كنتِ حاملًا أو ترضعين، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لإنجاب طفل، فاستشيري طبيبك قبل تناوُل هذا الدَّواء.<em> </em></p><p><em>&nbsp;</em></p><p><strong>يجب عدم استخدام عقار أبيليفاي مينتينا في السيدات الحوامل</strong></p><p>ما لم يتم مناقشة ذلك مع طبيبك. تأكدي من الاتصال بطبيبك فورً ا إذا أصبحت حاملاً أو كنت تعتقدين أنك حامل أو تنوين الحمل.<em> </em><em>&nbsp;</em></p><p>قد تحدث الأعراض التالية في الأطفال حديثي الولادة، وللأمهات اللاتي كنَّ قد استخدمن عقار أبيليفاي مينتينا في الثلث الأخير من الحمل (الثلاثة أشهر الأخيرة من الحمل): <em>&nbsp;</em></p><p>ارتعاش، وتصلب و / أو ضعف العضلات ونعاس وهِياج ومشاكل بالتنفس وصعوبة في التغذية.&nbsp; <em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>إذا حدث لطفلك أيٌّ من هذه الأعراض فقد تحتاجين إلى الاتصال بطبيبك.<em> </em></p><p><em>&nbsp;</em></p><p>إذا كنتِ تتناولين عقار أبيليفاي مينتينا، فسيناقش معكِ طبيبك ما إذا كان يجب أن ترضعين مع الأخذ في الاعتبار فوائد العلاج لك وفوائد الرضاعة الطبيعية لطفلك، حيث يجب ألا تقومي بفعل الأمرين معاً لذا تحدثي مع طبيبك حول أفضل الوسائل لتغذية طفلك إذا كنت تتناولين عقار أبيليفاي مينتينا.<em> </em></p><p><em>&nbsp;</em></p><p><strong>القيادة واستخدام الآلات</strong><em>&nbsp;</em></p><p>قد تحدث دوخة&nbsp; و مشاكل في في الرؤية أثناء العلاج بهذا الدواء (انظر القسم 4). يجب مراعاة ذلك في الحالات التي تتطلب اليقظة الكاملة، على سبيل المثال، عند قيادة السيارة او استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>أبيليفاي مينتينا يأتي على شكل مسحوق، الذي سوف يقوم طبيبك أو الممرضة باستعماله في تحضير المعلق. سيعطيك طبيبك حقنة واحدة في العضلة الألوية أو العضلة الدالية (الأرداف أو الكتف) كل شهر. قد تشعر ببعض الألم أثناء الحقن. سيقوم طبيبك بالتناوب في الحقن بين يمينك و يسارك. لن يتم إعطاء الحقن في الوريد.</p><p>طبيبك سيقرر جرعة أبيليفاي مينتينا المناسبة لك. الجرعة الموصى بها و جرعة البدء هي 400 ملغم، إلا إذا قرر طبيبك أن يعطيك جرعة منخفضة من البدء أو جرعة متابعة ( 300 ملغم، 200 ملغم أو 160 ملغم).</p><p>هناك طریقتان لبدء أبيليفاي مينيتينا ، سيقرر طبيبك الطريقة المناسبة لك:<br />&bull; إذا تم إعطاؤك حقنة واحدة من أبيليفاي مينتينا في يومك الأول، فسيستمر العلاج بمضاد الذهان الحالي عن طريق الفم لمدة<br />14 يومًا بعد الحقن الأول.<br />&bull; إذا تم إعطاؤك حقنتين من أبيليفاي مینتینا في يومك الأول، فستتناول أيضًا قرصًا واحداً من أريبيبرازول عن طريق الفم في ھذه<br />الزيارة.<br />. بعد ذلك، يتم إعطاء العلاج بحقن أبيليفاي مينتينا ما لم يخبرك طبيبك بخلاف ذلك.</p><p><strong>إذا كان يتم إعطاؤك كمية أكثر مما تحتاج من عقار أبيليفاي مينتينا:</strong><em> </em></p><p>سيتم إعطاؤك هذا الدَّواء تحت إشراف طبي؛ لذلك، فمن غير المحتمل ان يتم إعطاؤك كمية أكثر مما يجب. إذا كنت تزور أكثر من طبيب واحد، فتأكَّد من إخبارهم بأنك تتلقى عقار أبيليفاي مينتينا.<em> </em><em>&nbsp;</em></p><p>المرضى الذين قد تم إعطاؤهم كمية أكثر مما يجب من أريبيبرازول تعرضوا للأعراض التالية:<em> </em><em>&nbsp;</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب سريعة، هيجان/عصبية، مشاكل في الكلام.<em> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات غير معتادة (لا سيما الوجه واللسان) وانخفاض مستوى الوعي.<em> </em></p><p>وقد تشمل اعراض أخرى كالتالي:<em> </em></p><p><em>&nbsp;</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك/التباس، نوبات تشنجية (صرع)، غيبوبة، مزيج من الحمى والتنفسُّ السريع والتعرُّق <em>&nbsp;</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلبُّ العضلات والخمول أو النعاس، التنفسُّ ببطء، الاختناق، ارتفاع أو انخفاض ضغط الدَّم، ونظم قلبي غير طبيعي.<em> </em></p><p><em>&nbsp;</em></p><p>اتصل بطبيبك على الفور إذا عانيت من أ ي مما سبق.<em> </em></p><p><em>&nbsp;</em></p><p><strong>إذا أغفلت تناول إحدى حقن عقار أبيليفاي مينتينا </strong><em>&nbsp;</em></p><p>من المهم ألا تغفل عن أيَّ من الجرعات المقرَّرة. يجب إعطاؤك حقنة كل شهر، ولكن ليس قبل مرور 26 يوم من أخر حقنة.</p><p>إذا أغفلت تناول حقنة، فيجب عليك الاتصال بطبيبك للترتيب للحقنة التالية بأسرع وقت ممكن. إذا كانت لديك أيةَّ أسئلة إضافية حول استخدام هذا الدَّواء، استشر الطبيب أو الممرض(ة) الخاص بك.<em> </em></p><p><em>&nbsp;</em></p><p><strong>إذا توقفت عن تلقى عقار أبيليفاي مينتينا </strong><em>&nbsp;</em></p><p>لا توقف العلاج لمجرد أنك تشعر بتحسن. ولكن يجب أن تستمر في تلقي عقار أبيليفاي مينتينا طالما أخبرك الطبيب بذلك.<em> </em><em>&nbsp;</em></p><p>إذا كانت لديك أيةَّ أسئلة إضافية حول استخدام هذا الدَّواء، استشر الطبيب أو الممرض(ة) الخاص بك.<em> </em></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يسُبب هذا الدَّواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.&nbsp;<br />أخبر طبيبك فورًا إذا تعرضت لأي من الآثار الجانبية الخطيرة التالية:&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;إذا أصِبت بمزيج من أيٍ من هذه الأعراض التالية: نعاس مفرط، دوخة، ارتباك/التباس، التوهان، صعوبة بالكلام، صعوبة بالمشي، تصلبُّ بالعضلات أو الارتعاش، حمى، ضعف، هياج، عدوانية، قلق، ارتفاع ضغط الدَّم أو نوبة تشنُّجية يمكن أن تؤدي إلى فقدان الوعي. &nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;حركات غير معتادة خاصة بالوجه أو اللسان، إذ قد يرغب طبيبك في خفض الجرعة.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;جلطات الدم بالأوردة خاصةً بالساقين (وتشمل الأعراض: تورم، ألم، واحمرار بالساق)، والتي قد تنتقل عبر الأوعية الدموية إلى الرئتين وتتسبب في ألم بالصدر وصعوبة في التنفس. إذا لاحظت أي اً من هذه الأعراض فاطلب المشورة الطبية على الفور.&nbsp;<br />&nbsp;<br />مزيج من الحمى والتنفسُّ السريع والتعرُّق وتصلبُّ العضلات والخمول أو النعاس، إذ قد تكون هذه إحدى علامات حالة تسمى المُتلَازِمَةُ الخَبيثةَ للدَّواءِ المُضاد للذُّهان.&nbsp;<br />الشعور بالعطش أكثر من المعتاد، الحاجة للتبول بشكل أكثر من المعتاد، الشعور بالجوع الشديد، الشعور بالضعف، الشعور بالإعياء، الشعور بارتباك أو تكون رائحة الفم شبيهة برائحة الفواكه، إذ قد يكون ذلك من علامات مرض السُّكَّرِي.&nbsp;<br />قد تحدث أيضًا الآثار الجانبية المدرجة أدناه بعد استخدام عقار أبيليفاي مينتينا.&nbsp;<br />الآثار الجانبية الشائعة: (قد تؤُثر فيما يصل إلى 1 من بين كل 10 أشخاص) وهي كالاتي: &nbsp;&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;زيادة الوزن، فقدان الوزن.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;الشعور بالقلق، صعوبة في النوم (أرَق).&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;الشعور بالتململ وعدم القدرة على السكون، صعوبة الجلوس ساكنا، ارتجاف، الانتفاض العضلي غير المتحكم به، حركات تشنُّجية أو تلوي، تململ الساقين.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;تغيرات في مستوى الوعي لديك، نعاس.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;حركات عضلية لا يمكن التحكم فيها مثل التكشير وعض الشفتين وحركات باللسان. تظهر عادة في الوجه والفم أولا، لكن يمكنها أن تؤثر على أجزاء أخرى في الجسم، حيث يمكن أن تكون تلك علامات لحالة خطيرة تسمى &quot;خَللُ الحَرَكَةِ المُتأَخر&quot;.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;الباركنسونية: وهي مصطلح طبي يشمل العديد من الأعراض مثل تصلبُّ العضلات، التشنُّج عند ثني الأطراف، بطء أو قصور بحركات الجسم، عدم وجود تعبيرات على الوجه، شلل العضلات، جر القدمين، خطوات متسرعة، فقدان حركات الذراع الطبيعية عند السير.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;المقاومة المتشنجة للحركة السلبية حيث تشتد العضلات وترتخي، زيادة التوتر العضلي بشكل غير طبيعي، تصلبُّ العضلات، بطء حركة الجسم.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;دوخة، صداع.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;جفاف الفمَ.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;ألم عند موضع الحقن، تيبسُّ الجلد عند موضع الحقن.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;ضعف، فقدان القوة أو التعب الشديد.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;ارتفاع مستويات انزيم فوسفوكايناز الكْرياتين. &nbsp;<br />الآثار الجانبية غير الشائعة: (قد تؤُثر على ما يصل إلى 1 من كل 100 شخص):&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;زيادة أو فقدان الشهية، اضطراب حاسة التذَّوق والشم.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;انخفاض مستوى عدد نوع معين من خلايا الدَّ م البيضاء (قلة خلايا العَدِلات)، انخفاض الهيموجلوبين أو تعداد خلايا الدم الحمراء، انخفاض الصفائح الدَّموية.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;تفاعلات الحساسية (فرُط الحساسية).&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;انخفاض او ارتفاع مستوى هرمون البرولاكتين بالدَّم.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;ارتفاع السكر بالدَّم، انخفاض السكر بالدَّم. &nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;ارتفاع مستوي الدُّ هون بالدَّم مثل ارتفاع مستوى الكوليسترول، ارتفاع الدُّ هون الثلاثية، وأيضا انخفاض مستوى الكوليسترول وانخفاض مستوى الدُّ هون الثلاثية.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;ارتفاع مستويات الأنسولين وهو هرمون ينظم مستويات السكر بالدَّ م.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;أفكار حول الانتحار.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;اضطرابات عقلية تتميزَّ بنقص أو فقدان الاتصال بالواقع، الهلوسة، الأوهام.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;تغير أو ازدياد الرغبة الجنسية.&nbsp;<br />الهلع، الاكتئاب، تقَلَقلُ/تأرجح وجداني، حالة من عدم المبالاة مع انعدام العواطف، الشعور بانزعاج نفسي وعقلي، تغير الحالة المزاجية.&nbsp;<br />اضطراب النوم.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;الجز على الأسنان أو كزم الفك.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;فواق&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;ثبات مقلتي العينين في اتجاه واحد، عدم وضوح الرؤية، ألم بالعين، شفع (ازدواج البصر).&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;اضطراب في ضربات القلب، تباطؤ أو تسارع معدَّل ضربات القلب، اضطراب التوصيل الكهربائي للقلب، قراءة غير طبيعية لرسم القلب الكهربائي.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;دوخة عند النهوض من وضع الجلوس أو الرقود نتيجة لهبوط ضغط الدم، ارتفاع ضغط الدم.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;سعال. &nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;تهيُّج المعدة، عسر الهضم، ريال، زيادة افراز اللعاب من الفم عن المعدل الطبيعي، القيء، الغثيان، الإسهال، الإمساك، ألم أو عدم شعور بالراحة بالبطن، حركات معوية متكررة.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;اضطراب في قيم وظائف الكبد.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;تساقط غير طبيعي للشعر. &nbsp;&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;حب الشباب، حالة بجلد الوجه حيث يحدث احمرار للأنف والخدين بشكل غير معتاد، الأكزيما، تيبُس الجلد.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;تخشب عضَليِ، تقلُّصات عضلية، الانتفاض العضلي، تي بُّس عضلي، ألم عضلي، ألم بالأطراف، اضطراب بالمشي، ألم بالمفاصل، ألم بالظهر، انخفاض نطاق الحركة بالمفاصل، تصلب الرقبة، فتح محدود للفم.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;حصى بالكلى، وجود سكر بالبول.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;تضخم الثدي عند الرجال، الم بالثدي، جفاف بالمهبل.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;ضعف (فقدان القوة). &nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;ضيق بالصدر. &nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;تفاعُلات بموضع الحقن مثل الاحمرار والتورم والشعور بعدم الراحة والحكة في موضع الحقن. &nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;زيادة محيط الخصر.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;حساسية العين من الضوء.<br />&bull;&nbsp;&nbsp; &nbsp; المشي أثناء النوم (تم الإبلاغ عن هذا التأثير الضار في التجارب السريرية مع أريبيبرازول عن طريق الفم وليس أبيليفاي مينتينا)</p><p>تم الإبلاغ عن الآثار الجانبية التالية منذ بدء التسويق لأريبيبرازول عن طريق الفم، لكن مع دل تكرار حدوثها غير معروف وهي: &nbsp;<br />&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;انخفاض عدد خلايا الدم البيضاء.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;ضربات قلب غير معتادة، الوفاة المفاجئة غير معروفة الأسباب، نوبة قلبية.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;تفاعلات حساسية مثل تورم بالفم واللسان والوجه والحلق، الحكة، شرى (ارتكاريا)، طفح جلدي.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;الحُماض الكيتوني (تكوُّن كيتونات بالدَّم والبول) أو الغيبوبة، انخفاض مستوى الصوديوم في الدَّم لديك. &nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;فقدان الشهية، صعوبة البلع.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;العدوانية.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;العصبية، محاولة الانتحار والانتحار الفعلي؛ اضطراب الكلام، نوبة تشنجية، متلازمة السيرُوتوُنين&nbsp;<br />(تفاعل قد يسبب الشعور بسعادة غامرة، نعاس، طيش، التململ) الشعور بعدم ارتياح، الشعور بالثمالة، الحمى، تعرُّق، تيبسُّ العضلات (، مزيج من الحمى، تصلبُّ العضلات، التنفس بسرعة، التعرُّق، ضعف الوعي، تغيرات مفاجئة في ضغط الدَّم ومعدل ضربات القلب (المُتلَازِمَةُ الخَبيثةَ للدَّواءِ المُضاد للذُّهان). &nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;إغماء، تقلص العضلات حول الحنجرة، استنشاق الطعام بطريق الخطأ مع خطر الالتهاب الرئوي (عدوى الرئة)، التهاب البنكرياس.&nbsp;<br />فشل الكبد، التهاب الكبد، اصفرار الجلد وبياض العينين، الحساسية تجاه الضوء، تعرُّق مفرط، تي بُّس العضلات أو تقلصها، ألم عضلي، ضعف.&nbsp;<br />تبول لا إرادي (سلس البول)، صعوبة التبول.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;انتصاب مطول و / أو مؤلم.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;صعوبة التحكم في درجة حرارة الجسم أو فرط التدفئة، ألم بالصدر، وتورم باليدين أو الكاحلين أو القدمين.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;عدم القدرة على مقاومة الدافع أو القيادة أو الإغراء لتنفيذ إجراء قد يكون ضارًا لك أو للآخرين ، والذي قد يتضمن:<br />&bull;&nbsp;&nbsp; &nbsp;دافع قوي للمقامرة بشكل مفرط على الرغم من العواقب الشخصية أو العائلية الخطيرة<br />&bull;&nbsp;&nbsp; &nbsp;تغيير أو زيادة الاهتمام والسلوك الجنسيين اللذين يشكلان مصدر قلق كبير لك أو للآخرين ، على سبيل المثال ، زيادة الدافع الجنسي&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;التسوق المفرط لا يمكن السيطرة عليه<br />&bull;&nbsp;&nbsp; &nbsp;الشراهة عند تناول الطعام (تناول كميات كبيرة من الطعام في فترة زمنية قصيرة) أو تناول الطعام القهري (تناول المزيد من الطعام أكثر من المعتاد وأكثر مما يلزم لإشباع جوعك)<br />&bull;&nbsp;&nbsp; &nbsp;ميل للتجول بعيدا<br />- تفاعلات حساسية خطيرة مثل تفاعل الدواء مع فرط الحمضات والأعراض الجهازية . تبدو في البداية تشبه الأنفلونزا أعراض مع طفح جلدي على الوجه ثم طفح جلدي ممتد ، ارتفاع درجة الحرارة ، تضخم الغدد الليمفاوية ، زيادة مستويات أنزيمات الكبد التي تظهر في فحوصات الدم وزيادة في نوع خلية الدم البيضاء &nbsp;(فرط الحمضات).</p><p><br />&bull;&nbsp;&nbsp; &nbsp;أخبر طبيبك إذا واجهت أي من هذه السلوكيات ؛ سوف يناقش طرق إدارة أو تقليل الأعراض.</p><p>الإبلاغ عن الآثار الجانبية:&nbsp;<br />إذا ظهرت لديك أيَّة آثار جانبية، تحدث إلى الطبيب أو الممرض(ة) الخاص بك. بما في ذلك أيةَّ آثار جانبية مُحتمَلة، غير المُدرجة في هذه النشَّرة. لأنه من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.&nbsp;<br />&nbsp;<br />&nbsp;</p><p><br />ﻟﻺﺑﻼغ ﻋﻦ اﻷﻋﺮاض اﻟﺠﺎﻧﺒﯿﺔ:</p><p>&bull;&nbsp;&nbsp; &nbsp; &nbsp;اﻟﻤﻤﻠﻜﺔ اﻟﻌﺮﺑﯿﺔ اﻟﺴﻌﻮدﯾﺔ:</p><p>المركز الوطني للتيقظ الدوائي</p><p>. &nbsp; &nbsp;مركز الاتصال الموحد : 19999<br />. &nbsp; &nbsp;البريد الالكتروني: npc.drug@sfda.gov.sa<br />. &nbsp; &nbsp;الموقع الالكتروني: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; &nbsp;دول الخليج الأخرى&nbsp;<br />الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.&nbsp;<br />&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>احتفظ بهذا الدَّواء بعيدًا عن رؤية ومتناول الأطفال.<em> </em><em>&nbsp;</em></p><p>لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الكرتونيةَّ.&nbsp; يشُير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.<em> </em></p><p>لا يخزن في درجة حرارة تتجاوز 30 درجة مئوية.<em> </em></p><p>لا يُجُمد.<em> </em></p><p>يجب استخدام المعلق المحضَّر فورً ا، ويمكن تخزينه في درجة حرارة أقل من 25 درجة مئوية لمدة تصل إلى 4 ساعات في الزجاجة. لا تخُزن المعلق المحضَّر في الحٌقنة.<em> </em></p><p>لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التخَّلص من الأدوية التي لم تعُ د تستخدمها، سوف تسُاعد هذه الإجراءات في الحفاظ على البيئة.<em> </em></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّ الة هي أريبيبرازول.<em> </em></p><p>تحتوي كل زجاجة على 400 مجم أريبيبرازول.<em> </em></p><p>بعد الإعداد يحتوي كل مللي لتر من المعلق على 200 مجم أريبيبرازول.<em> </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: <em>&nbsp;</em></p><p><u>المسحوق</u>:<em> </em></p><p>كارميلوز الصوديوم، مانيتول، فوسفات ثنائي هيدروجين الصوديوم أحادي الهيدرات، هيدروكسيد الصوديوم.<em> </em></p><p><u>المذيب</u>:</p><p>ماء للحقن.<em> </em></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>عقار أبيليفاي مينتينا هو مسحوق ومُذيب لإعداد معلق ممتد المفعول للحقن. يتوافر عقار أبيليفاي مينتينا على هيئة مسحوق ذي لون أبيض إلى أبيض مائل للصفرة في زجاجة شفافة، سيقوم الطبيب أو الممرض(ة) الخاص بك بتحضيره على هيئة معلق يتم إعطاؤه كحقنة باستخدام زجاجة مذيب خاصة بعقار أبيليفاي مينتينا التي تأتي كمحلول صافي في زجاجة شفافة. تحتوي كل عبوة على زجاجة مسحوق واحدة وزجاجة مذيب واحدة. قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك حق التسَّويق&nbsp; </strong></p><p>إتش لوندبيك أيه/أس<em> </em>أوتيليافيج 9، 2500 فالبي<em> </em>الدانمارك<em> </em></p><p><em>&nbsp;</em></p><p><strong>الشركة المصنعة</strong></p><p>إتش لوندبيك أيه/أس</p><p><em>&nbsp;</em>أوتيليافيج 9، 2500</p><p>فالبي<em> </em>الدانمارك</p><p><em>&nbsp;</em></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النَّشرة في:2023-05
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 400 mg aripiprazole.
After reconstitution each ml of suspension contains 200 mg aripiprazole.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for prolonged-release suspension for injection
Powder: white to off-white
Solvent: clear solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Abilify Maintena is indicated for the treatment of schizophrenia.<br />Maintenance monotherapy treatment of bipolar I disorder in adults</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Recommended Dosage and Dosage Adjustment</u></p><p><u>&nbsp;</u></p><p>For patients who have never taken aripiprazole, tolerability with oral aripiprazole must occur prior to initiating treatment with Abilify Maintena.</p><p><strong>&nbsp;</strong></p><p>Titration of the dose for Abilify Maintenais not required. The starting dose can be administered by following one of two regimens:</p><p>&bull; One injection start: On the day of initiation, administer one injection of 400 mg Abilify Maintena and continue treatment with 10 mg to 20 mg oral aripiprazole per day for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy.</p><p>&bull; Two injection start: On the day of initiation, administer two separate injections of 400 mg Abilify Maintena at separate injection sites (see method of administration), along with one 20 mg dose of oral aripiprazole.</p><p>After the injection start, the recommended maintenance dose of Abilify Maintena is 400 mg.</p><p>Abilify Maintena should be administered once monthly as a single injection (no sooner than 26 days after the previous injection).</p><p>&nbsp;</p><p><u>Switching from oral antipsychotics</u></p><p>For patients already stable on another oral antipsychotic (and known to tolerate aripiprazole), after the first ABILIFY MAINTENA injection, continue treatment with the oral antipsychotic for 14 consecutive days to maintain therapeutic antipsychotic concentrations during initiation of therapy).</p><p>&nbsp;</p><p><u>Switching from long-acting injectable antipsychotics</u></p><p><u>&nbsp;</u></p><p>For patients who have never taken oral or injectable aripiprazole, establish tolerability with</p><p>oral aripiprazole prior to initiating treatment with Abilify Maintena. When switching patients</p><p>from previous long-acting injectable antipsychotics, initiate Abilify Maintena therapy in</p><p>place of the next scheduled injection, with 14 days of concurrent oral aripiprazole. Abilify</p><p>Maintena should then be continued monthly.</p><p>&nbsp;</p><p>&nbsp;</p><p>If there are adverse reactions with the 400&nbsp;mg dosage, reduction of the dose to 300&nbsp;mg once monthly should be considered.</p><p><u>&nbsp;</u></p><p><u>Missed doses</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Missed doses</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Timing of missed dose</strong></p><p>&nbsp;</p><p><strong>If 2<sup>nd</sup> or 3<sup>rd</sup>&nbsp;dose is missed and time since last injection is:</strong></p></td><td style="vertical-align:top"><p><strong>Action</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt;&nbsp;4&nbsp;weeks and &lt;&nbsp;5&nbsp;weeks</p></td><td style="vertical-align:top"><p>The injection should be administered as soon as possible and then resume monthly injection schedule.</p></td></tr><tr><td style="vertical-align:top"><p>&gt;&nbsp;5&nbsp;weeks</p></td><td style="vertical-align:top"><p>Concomitant oral aripiprazole should be restarted for 14 days with next administered injection or two separate injections given at one time, along with a single dose of 20 mg oral aripiprazole. Monthly injection schedule should be then resume.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>If 4<sup>th</sup> or subsequent doses are missed (i.e., after attainment of steady state) and time since last injection is:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;&nbsp;4&nbsp;weeks and &lt;&nbsp;6&nbsp;weeks</p></td><td style="vertical-align:top"><p>The injection should be administered as soon as possible&nbsp;and then the monthly injection schedule should be resumed.</p></td></tr><tr><td style="vertical-align:top"><p>&gt;&nbsp;6&nbsp;weeks</p></td><td style="vertical-align:top"><p>Concomitant oral aripiprazole should be restarted for 14 days with next administered injection or two separate injections given at one time, along with a single dose of 20 mg oral aripiprazole. Monthly injection schedule should be resumed.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly patients</em></p><p>The safety and efficacy of Abilify Maintena in the treatment of schizophrenia in patients 65&nbsp;years of age or older has not been established (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dosage adjustment is required for patients with renal impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dosage adjustment is required for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. In these patients requiring cautious dosing, oral formulation should be preferred (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Known CYP2D6 poor metabolisers</em></p><p>In patients who are known to be CYP2D6 poor metabolisers :</p><p> One injection start: The starting dose should be 300 mg Abilify Maintena and continue treatment with prescribed dose of oral aripiprazole per day for 14 consecutive days.</p><p> Two injection start: The starting dose should be 2 separate injections of 300 mg Abilify Maintena (see method of administration) along with one single dose of the previous prescribed dose of oral aripiprazole.</p><p>In patients who are known to be CYP2D6 poor metabolisers and concomitantly use a strong CYP3A4 inhibitors:</p><p> The one injection start: the dose should be reduced to 200 mg (see section 4.5) and continue treatment with the prescribed dose of oral aripiprazole per day for 14 consecutive days.</p><p> Two injection start is not to be used in patients who are known to be CYP2D6 poor metabolisers and concomitantly use a strong CYP3A4 inhibitor. After the injection start, see table below for the recommended maintenance dose of Abilify Maintena. Abilify Maintena should be administered once monthly as a single injection (no sooner than 26 days after the previous injection).</p><p><em>&nbsp;</em></p><p>Maintenance dose adjustments due to interactions with CYP2D6 and/or CYP3A4 inhibitors and/or CYP3A4 inducers</p><p>Maintenance dosage adjustments should be&nbsp;made&nbsp;in patients taking concomitant strong CYP3A4 inhibitors or strong CYP2D6 inhibitors for more than 14&nbsp;days. If the CYP3A4 inhibitor or CYP2D6 inhibitor is withdrawn, the dosage may need to be increased to the previous dose (see section&nbsp;4.5). In case of adverse reactions despite dose adjustments of Abilify Maintena, the necessity of concomitant use of CYP2D6 or CYP3A4 inhibitor should be reassessed.</p><p>&nbsp;</p><p>Concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided for more than 14&nbsp;days because the blood levels of aripiprazole are decreased and may be below the effective levels (see section&nbsp;4.5).</p><p>&nbsp;</p><p><strong>Maintenance&nbsp;dose adjustments of Abilify Maintena in patients who are taking concomitant strong CYP2D6 inhibitors, strong CYP3A4 inhibitors, and/or CYP3A4 inducers for more than 14&nbsp;days</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:548px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Adjusted dose</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Patients taking 400&nbsp;mg of Abilify Maintena</strong></p></td></tr><tr><td style="vertical-align:top"><p>Strong CYP2D6 or strong CYP3A4 inhibitors</p></td><td style="vertical-align:top"><p>300&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>Strong CYP2D6 and strong CYP3A4 inhibitors</p></td><td style="vertical-align:top"><p>200&nbsp;mg</p></td></tr><tr><td><p>CYP3A4 inducers</p></td><td style="vertical-align:top"><p>Avoid use</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Patients taking 300&nbsp;mg of Abilify Maintena</strong></p></td></tr><tr><td style="vertical-align:top"><p>Strong CYP2D6 or strong CYP3A4 inhibitors</p></td><td style="vertical-align:top"><p>200&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>Strong CYP2D6 and strong CYP3A4 inhibitors</p></td><td style="vertical-align:top"><p>160&nbsp;mg</p></td></tr><tr><td><p>CYP3A4 inducers</p></td><td style="vertical-align:top"><p>Avoid use</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety and efficacy of Abilify Maintena in children and adolescents aged 0‑17&nbsp;years have not been established. No data are available.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>Abilify Maintena is only intended for intramuscular use and should not be administered intravenously or subcutaneously. It should only be administered by a healthcare professional. The suspension should be injected immediately after reconstitution but can be stored below 25&nbsp;&deg;C for up to 4&nbsp;hours in the vial. The suspension should be injected slowly as a single injection (doses must not be divided) into the gluteal or deltoid muscle. Care should be taken to avoid inadvertent injection into a blood vessel. Sites of injections should be rotated between the two gluteal or deltoid muscles.</p><p>If initiating with the two injection start, inject into two different sites in two different muscles. DO NOT inject both injections concomitantly into the same deltoid or gluteal muscle. For known CYP2D6 poor metabolisers administer in either two separate deltoid muscles or one deltoid and one gluteal muscle. DO NOT inject into two gluteal muscles. Full instructions for use and handling of Abilify Maintena are provided in the package leaflet (information intended for healthcare professionals).</p><p>&nbsp;</p><p>The recommended needle for gluteal administration is a 38&nbsp;mm (1.5&nbsp;inch), 22&nbsp;gauge hypodermic safety needle. For obese patients (Body mass index &gt; 28 kg/m<sup>2</sup>), a 51&nbsp;mm (2&nbsp;inch), 21&nbsp;gauge hypodermic safety needle should be used (see section&nbsp;6.6).&nbsp;</p><p>The recommended needle for deltoid administration is a 25&nbsp;mm (1&nbsp;inch), 23&nbsp;gauge hypodermic safety needle. For obese patients, a 38&nbsp;mm (1.5&nbsp;inch), 22&nbsp;gauge hypodermic safety needle should be used (see section&nbsp;6.6).</p><p>&nbsp;</p><p>The powder and solvent vials are for single-use only.</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During antipsychotic treatment, improvement in the patient&#39;s clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period.</p><p>&nbsp;</p><p><u>Use in patients who are in an acutely agitated or severely psychotic state</u></p><p>Abilify Maintena should not be used to manage acutely agitated or severely psychotic states when immediate symptom control is warranted.</p><p>&nbsp;</p><p><u>Suicidality</u></p><p>The occurrence of suicidal behaviour is inherent in psychotic illnesses, and in some cases has been reported early after initiation or switch of antipsychotic treatment, including treatment with aripiprazole (see section&nbsp;4.8). Close supervision of high risk patients should accompany antipsychotic treatment.</p><p>&nbsp;</p><p><u>Cardiovascular disorders</u></p><p>Abilify Maintena should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant.</p><p>&nbsp;</p><p>Cases of venous thromboembolism (VTE) have been reported with antipsychotic medicinal products. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Abilify Maintena and preventive measures undertaken (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>QT prolongation</u></p><p>In clinical trials of treatment with oral aripiprazole, the incidence of QT prolongation was comparable to placebo. Aripiprazole should be used with caution in patients with a family history of QT prolongation (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Tardive dyskinesia</u></p><p>In clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive dyskinesia appear in a patient on Abilify Maintena, dose reduction or discontinuation of should be considered (see section&nbsp;4.8). These symptoms can temporally deteriorate or can even arise after discontinuation of treatment.</p><p>&nbsp;</p><p><u>Neuroleptic Malignant Syndrome (NMS)</u></p><p>NMS is a potentially fatal symptom complex associated with antipsychotic medicinal products. In clinical trials, rare cases of NMS were reported during treatment with aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.</p><p>&nbsp;</p><p>However, elevated creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have also been reported. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotic medicinal products, including aripiprazole, must be discontinued (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Seizure</u></p><p>In clinical trials, uncommon cases of seizure were reported during treatment with aripiprazole. Therefore, aripiprazole should be used with caution in patients who have a history of seizure disorder or have conditions associated with seizures (see section&nbsp;4.8).</p><p><u>&nbsp;</u></p><p><u>Elderly patients with dementia-related psychosis</u></p><p><em>Increased mortality</em></p><p>In three placebo-controlled trials of oral aripiprazole in elderly patients with psychosis associated with Alzheimer&#39;s disease (n&nbsp;=&nbsp;938; mean age: 82.4&nbsp;years; range: 56‑99&nbsp;years), patients treated with aripiprazole are at an increased risk of death compared to placebo. The rate of death in oral aripiprazole-treated patients was 3.5&nbsp;% compared to 1.7&nbsp;% in the placebo group. Although the causes of deaths were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature (see section&nbsp;4.8).</p><p><u>&nbsp;</u></p><p><em>Cerebrovascular adverse reactions</em></p><p>In the same trials with oral aripiprazole, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84&nbsp;years; range: 78‑88&nbsp;years). Overall, 1.3&nbsp;% of oral aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6&nbsp;% of placebo-treated patients in these trials. This difference was not statistically significant. However, in one of these trials, a fixed-dose trial, there was a significant dose response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Abilify Maintena is not indicated for the treatment of patients with dementia-related psychosis.</p><p>&nbsp;</p><p><u>Hyperglycaemia and diabetes mellitus</u></p><p>Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotic medicines, including aripiprazole. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes. In clinical trials with aripiprazole, there were no significant differences in the incidence rates of hyperglycaemia-related adverse reactions (including diabetes) or in abnormal glycaemia laboratory values compared to placebo. Precise risk estimates for hyperglycaemia-related adverse reactions in patients treated with aripiprazole and with other atypical antipsychotic medicines are not available to allow direct comparisons. Patients treated with any antipsychotic medicinal products, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>Hypersensitivity reactions, characterised by allergic symptoms, may occur with aripiprazole.</p><p><u>&nbsp;</u></p><p><u>Weight gain</u></p><p>Weight gain is commonly seen in schizophrenic patients due to use of antipsychotics known to cause weight gain, co-morbidities, poorly managed life-style and might lead to severe complications. Weight gain has been reported post-marketing among patients prescribed oral aripiprazole. When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain (see section 4.8).</p><p>&nbsp;</p><p><u>Dysphagia</u></p><p>Oesophageal dysmotility and aspiration have been associated with antipsychotic medicinal product use, including aripiprazole. Aripiprazole should be used cautiously in patients at risk for aspiration pneumonia.</p><p><u>&nbsp;</u></p><p><u>Pathological gambling</u><em><u> and other impulse control disorders</u></em></p><p><em>Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. Other urges, reported, include: increased sexual urges, compulsive shopping, binge or compulsive eating, and other impulsive and compulsive behaviours. It is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with aripiprazole. It should be noted that impulse-control symptoms can be associated with the underlying disorder; however, in some cases, urges were reported to have stopped when the dose was reduced or the medication was discontinued. Impulse control disorders may result in harm to the patient and others if not recognised. Consider dose reduction or stopping the medication if a patient develops such urges while taking aripiprazole (see section 4.8).</em></p><p><em>&nbsp;</em></p><p><u>Falls</u></p><p>&nbsp;</p><p>Aripiprazole may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls. Caution should be taken when treating patients at higher risk, and a lower starting dose should be considered (e.g., elderly or debilitated patients; see section&nbsp;4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific interaction studies have been performed with Abilify Maintena. The information below is obtained from studies with oral aripiprazole.</p><p>&nbsp;</p><p>Due to its &alpha;1-adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive medicinal products.</p><p>&nbsp;</p><p>Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administered in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation (see section&nbsp;4.8).</p><p>&nbsp;</p><p>If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used.</p><p>&nbsp;</p><p><u>Potential for other medicinal products to affect Abilify Maintena</u></p><p><u>&nbsp;</u></p><p>Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes, but not CYP1A enzymes. Thus, no dosage adjustment is required for smokers.</p><p>&nbsp;</p><p><em>Quinidine and other strong CYP2D6 inhibitors</em></p><p>In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107&nbsp;%, while C<sub>max</sub> was unchanged. The AUC and C<sub>max</sub> of dehydro-aripiprazole, the active metabolite, decreased by 32&nbsp;% and 47&nbsp;%, respectively. Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reduction should, therefore, be applied (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Concomitant use of Abilify Maintena with quinidine or other CYP2D6 inhibitors increases the concentrations of aripiprazole after longer-term use (i.e., over 14 days) and reduction of the Abilify Maintena is recommended.</p><p><em>&nbsp;</em></p><p><em>Ketoconazole and other strong CYP3A4 inhibitors</em></p><p>In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and C<sub>max</sub> by 63&nbsp;% and 37&nbsp;%, respectively. The AUC and C<sub>max</sub> of dehydro-aripiprazole increased by 77&nbsp;% and 43&nbsp;%, respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolisers (see section&nbsp;4.2).</p><p>&nbsp;</p><p>When considering concomitant administration of ketoconazole or other potent CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient. Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should, therefore, be applied (see section&nbsp;4.2).</p><p>Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of Abilify Maintena should be increased to the dose prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g., diltiazem) or CYP2D6 (e.g., escitalopram) are used concomitantly with this medicinal product, modest increases in plasma aripiprazole concentrations may be expected.</p><p>&nbsp;</p><p>Concomitant use of Abilify Maintena with ketoconazole or other CYP3A4 inhibitors for more than 14 days increases the concentrations of aripiprazole and reduction of the Abilify Maintena dose is recommended.</p><p><em>&nbsp;</em></p><p><em>Carbamazepine and other CYP3A4 inducers</em></p><p>Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole<strong><em> </em></strong>to patients with schizophrenia or schizoaffective disorder, the geometric means of C<sub>max</sub> and AUC for aripiprazole were 68&nbsp;% and 73&nbsp;% lower, respectively, compared to when oral aripiprazole (30&nbsp;mg) was administered alone. Similarly, for dehydro-aripiprazole the geometric means of C<sub>max</sub> and AUC after carbamazepine co-administration were 69&nbsp;% and 71&nbsp;% lower, respectively, than those following treatment with oral aripiprazole alone.</p><p>&nbsp;</p><p>Concomitant administration of Abilify Maintena and other inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John&#39;s Wort) may be expected to have similar effects. The concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided because the blood levels of aripiprazole are decreased and may be below the effective levels.</p><p>&nbsp;</p><p><em>Valproate and lithium</em></p><p>When either valproate or lithium was administered concomitantly with aripiprazole, there was no clinically significant change in aripiprazole concentrations, and, therefore, no dose adjustment is necessary when either valproate or lithium is administered with Abilify Maintena.</p><p>&nbsp;</p><p><u>Potential for Abilify Maintena to affect other medicinal products</u></p><p>&nbsp;</p><p>In clinical studies, oral doses of 10‑30&nbsp;mg/day of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3‑methoxymorphinan ratio), 2C9 (warfarin), 2C19 (omeprazole), and 3A4 (dextromethorphan). Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism <em>in vitro</em>. Thus, Abilify Maintena is unlikely to cause clinically important medicinal product interactions mediated by these enzymes.</p><p>&nbsp;</p><p>When aripiprazole was administered concomitantly with lamotrigine, dextromethorphan, warfarin, omeprazole, escitalopram, or venlafaxine there was no clinically important change in concentrations of these medicinal products.&nbsp; Thus, no dosage adjustment of these medicinal products is required when co-administered with Abilify Maintena.</p><p>&nbsp;</p><p><em>Serotonin syndrome</em></p><p>Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as SSRI/SNRI, or with medicinal products that are known to increase aripiprazole concentrations (see section&nbsp;4.8).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are no adequate and well-controlled trials of aripiprazole in pregnant women. Congenital anomalies have been reported; however, causal relationship with aripiprazole could not be established. Animal studies could not exclude potential developmental toxicity (see section&nbsp;5.3). Patients must be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with Abilify Maintena. Due to insufficient safety information in humans and concerns raised by animal reproductive studies, this medicinal product should not be used in pregnancy unless the expected benefit clearly justifies the potential risk to the foetus.</p><p>&nbsp;</p><p>Prescribers need to be aware of the long-acting properties of Abilify Maintena.</p><p>&nbsp;</p><p>New-born infants exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, new-born infants should be monitored carefully (see section&nbsp;4.8).</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p>Aripiprazole is excreted in human breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Abilify Maintena therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Aripiprazole did not impair fertility based on data from reproductive toxicity studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Abilify Maintena can have minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section&nbsp;4.8). Therefore, patients should be advised not to drive or operate machines until their individual susceptibility to this medicinal product is known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To reports any side effect(s)</p><p>Saudi Arabia:&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;The National Pharmacovigilance Centre (NPC):&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;SFDA Call Center: 19999&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;E-mail: npc.drug@sfda.gov.sa&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;Website: https://ade.sfda.gov.sa/&nbsp;</p><p>Other GCC States:&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;Please contact the relevant competent authority.<br />&nbsp;</p><p>&nbsp;</p><p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>The most frequently observed adverse drug reactions (ADRs) reported in &ge;&nbsp;5&nbsp;% of patients in two double-blind controlled clinical trials of Abilify Maintena were weight increased (9.0&nbsp;%), akathisia (7.9&nbsp;%), insomnia (5.8&nbsp;%), and injection site pain (5.1&nbsp;%).</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>The incidences of the Adverse Drug Reactions (ADRs) associated with aripiprazole therapy are tabulated below. The table is based on adverse events reported during clinical trials and/or post-marketing use.</p><p>&nbsp;</p><p>All ADRs are listed by system organ class and frequency; very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports. Consequently, the frequency of these adverse events is qualified as &quot;not known&quot;.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Neutropenia</p><p>Anaemia</p><p>Thrombocytopenia</p><p>Neutrophil count decreased</p><p>White blood cell count decreased</p></td><td style="vertical-align:top"><p>Leukopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reaction (e.g. anaphylactic reaction, angioedema including swollen tongue, tongue oedema, face oedema, pruritus, or urticaria)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood prolactin decreased</p><p>Hyperprolactinaemia</p></td><td style="vertical-align:top"><p>Diabetic hyperosmolar coma</p><p>Diabetic ketoacidosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Weight increased</p><p>Diabetes mellitus</p><p>Weight decreased</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p><p>Hypercholesterolaemia</p><p>Hyperinsulinaemia</p><p>Hyperlipidaemia</p><p>Hypertriglyceridaemia</p><p>Appetite disorder</p></td><td style="vertical-align:top"><p>Anorexia</p><p>Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Agitation</p><p>Anxiety</p><p>Restlessness</p><p>Insomnia</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Suicidal ideation</p><p>Psychotic disorder</p><p>Hallucination</p><p>Delusion</p><p>Hypersexuality</p><p>Panic reaction</p><p>Depression</p><p>Affect lability</p><p>Apathy</p><p>Dysphoria</p><p>Sleep disorder</p><p>Bruxism</p><p>Libido decreased</p><p>Mood altered</p><p>Somnambulism*</p></td><td style="vertical-align:top"><p>Completed suicide</p><p>Suicide attempt</p><p>Pathological gambling</p><p><em>Impulse-control disorders</em></p><p><em>Binge eating</em></p><p><em>Compulsive shopping</em></p><p><em>Poriomania</em></p><p>Nervousness</p><p>Aggression</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Extrapyramidal disorder</p><p>Akathisia</p><p>Tremor</p><p>Dyskinesia</p><p>Sedation</p><p>Somnolence</p><p>Dizziness</p><p>Headache</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dystonia</p><p>Tardive dyskinesia</p><p>Parkinsonism</p><p>Movement disorder</p><p>Psychomotor hyperactivity</p><p>Restless legs syndrome</p><p>Cogwheel rigidity</p><p>Hypertonia</p><p>Bradykinesia</p><p>Drooling</p><p>Dysgeusia</p><p>Parosmia</p></td><td style="vertical-align:top"><p>Neuroleptic malignant syndrome</p><p>Grand mal convulsion Serotonin syndrome</p><p>Speech disorder</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oculogyric crisis</p><p>Vision blurred</p><p>Eye pain</p><p>Diplopia</p><p>Photophobia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ventricular extrasystoles</p><p>Bradycardia</p><p>Tachycardia</p><p>Electrocardiogram T wave amplitude decreased</p><p>Electrocardiogram abnormal</p><p>Electrocardiogram T wave inversion</p></td><td style="vertical-align:top"><p>Sudden unexplained death</p><p>Cardiac arrest</p><p>Torsades de pointes Ventricular arrhythmias</p><p>QT prolongation</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypertension</p><p>Orthostatic hypotension</p><p>Blood pressure increased</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Syncope</p><p>Venous thromboembolism (including pulmonary embolism and deep vein thrombosis)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough</p><p>Hiccups</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oropharyngeal spasm</p><p>Laryngospasm</p><p>Aspiration pneumonia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Dry mouth</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gastrooesophageal reflux disease</p><p>Dyspepsia</p><p>Vomiting</p><p>Diarrhoea</p><p>Nausea</p><p>Abdominal pain upper</p><p>Abdominal discomfort</p><p>Constipation</p><p>Frequent bowel movement</p><p>Salivary hypersecretion</p></td><td style="vertical-align:top"><p>Pancreatitis</p><p>Dysphagia</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Liver function test abnormal</p><p>Hepatic enzyme increased</p><p>Alanine aminotransferase increased</p><p>Gamma-glutamyl transferase increased</p><p>Blood bilirubin increased</p><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>Hepatic failure</p><p>Jaundice</p><p>Hepatitis</p><p>Alkaline phosphatase increased</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alopecia</p><p>Acne</p><p>Rosacea</p><p>Eczema</p><p>Skin induration</p></td><td style="vertical-align:top"><p>Rash</p><p>Photosensitivity reaction</p><p>Hyperhidrosis</p><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Musculoskeletal stiffness&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle rigidity</p><p>Muscle spasms</p><p>Muscle twitching</p><p>Muscle tightness</p><p>Myalgia</p><p>Pain in extremity</p><p>Arthralgia</p><p>Back pain</p><p>Joint range of motion decreased</p><p>Nuchal rigidity</p><p>Trismus</p></td><td style="vertical-align:top"><p>Rhabdomyolysis</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nephrolithiasis</p><p>Glycosuria</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urinary retention, Urinary incontinence</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pregnancy, puerperium and perinatal conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Drug withdrawal syndrome neonatal (see section 4.6)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>Erectile dysfunction</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Galactorrhoea</p><p>Gynaecomastia</p><p>Breast tenderness</p><p>Vulvovaginal dryness</p></td><td style="vertical-align:top"><p>Priapism</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Injection site pain</p><p>Injection site induration Fatigue</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia</p><p>Asthenia</p><p>Gait disturbance</p><p>Chest discomfort</p><p>Injection site reaction</p><p>Injection site erythema</p><p>Injection site swelling</p><p>Injection site discomfort</p><p>Injection site pruritus</p><p>Thirst</p><p>Sluggishness</p></td><td style="vertical-align:top"><p>Temperature regulation disorder (e.g. hypothermia, pyrexia)</p><p>Chest pain</p><p>Peripheral oedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Blood creatine phosphokinase increased</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood glucose increased</p><p>Blood glucose decreased</p><p>Glycosylated haemoglobin increased</p><p>Waist circumference increased</p><p>Blood cholesterol decreased</p><p>Blood triglycerides decreased</p></td><td style="vertical-align:top"><p>Blood glucose fluctuation</p></td></tr></tbody></table><p>&nbsp;</p><p>(*) This adverse reaction has been reported in clinical trials with oral aripiprazole and has not been reported for Abilify Maintena.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>&nbsp;</em></p><p><em>Injection site reactions </em></p><p>During the double‑blind, controlled phases of the two trials, injection site reactions were observed; those seen were generally mild to moderate in severity, and resolved over time. Injection site pain (incidence 5.1&nbsp;%), has a median onset on day&nbsp;2 after the injection and a median duration of 4&nbsp;days.</p><p>&nbsp;</p><p>In an open label study comparing bioavailability of Abilify Maintena administered in the deltoid or gluteal muscle, injection site related reactions were slightly more frequent in the deltoid muscle. The majority were mild and improved on subsequent injections When compared to studies where Abilify Maintena was injected in the gluteal muscle, repeated occurrence of injection site pain is more frequent in the deltoid muscle.</p><p>&nbsp;</p><p><em>Leukopenia</em></p><p>Neutropenia has been reported in the clinical program with Abilify Maintena and typically starts around day&nbsp;16 after first injection, and lasts a median of 18&nbsp;days.</p><p>&nbsp;</p><p><em>Extrapyramidal Symptoms (EPS)</em></p><p>In trials in stable patients with schizophrenia, Abilify Maintena was associated with a higher frequency of EPS symptoms (18.4 %) than oral aripiprazole treatment (11.7 %). Akathisia was the most frequently observed symptom (8.2 %) and typically starts around day 10 after first injection, and lasts a median of 56 days.</p><p>&nbsp;</p><p>Subjects with akathisia typically received anti-cholinergic medicines as treatment, primarily benzatropine mesilate and trihexyphenidyl. Less often substances such as propranolol and benzodiazepines (clonazepam and diazepam) were administered to control akathisia.</p><p>&nbsp;</p><p>Parkinsonism events followed in frequency (6.9 % Abilify Maintena, 4.15 % oral aripiprazole 10-30 mg tablets group and 3.0 % placebo, respectively).</p><p>&nbsp;</p><p><em>Dystonia</em></p><p>Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic medicinal products. An elevated risk of acute dystonia is observed in males and younger age groups.</p><p>&nbsp;</p><p><em>Weight</em></p><p>During the double-blind, active-controlled phase of the 38‑week trial, the incidence of weight gain of &sup3;&nbsp;7&nbsp;% from baseline to last visit was 9.5&nbsp;% for Abilify Maintena group and 11.7&nbsp;% for the oral aripiprazole tablets 10‑30&nbsp;mg group.&nbsp; The incidence of weight loss of &ge;&nbsp;7&nbsp;% from baseline to last visit was 10.2&nbsp;% for Abilify Maintena and 4.5&nbsp;% for oral aripiprazole tablets 10‑30&nbsp;mg.</p><p>&nbsp;</p><p>During the double-blind, placebo-controlled phase of the 52‑week trial, the incidence of weight gain of &sup3;&nbsp;7&nbsp;% from baseline to last visit was 6.4&nbsp;% for the Abilify Maintena group and 5.2&nbsp;% for the placebo group. The incidence of weight loss of &ge;&nbsp;7&nbsp;% from baseline to last visit was 6.4&nbsp;% for the Abilify Maintena group and 6.7&nbsp;% for the placebo group. During double-blind treatment, mean change in body weight from baseline to last visit was ‑0.2&nbsp;kg for Abilify Maintena and ‑0.4&nbsp;kg for placebo (p&nbsp;=&nbsp;0.812).</p><p>&nbsp;</p><p><em>Prolactin</em></p><p>In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section&nbsp;5.1).</p><p>&nbsp;</p><p><em>Pathological gambling and other impulse control disorders</em></p><p><em>Pathological gambling, hypersexuality, compulsive shopping and binge or compulsive eating can occur in patients treated with aripiprazole (see section 4.4).</em></p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No cases of overdose associated with adverse reactions were reported in clinical studies with Abilify Maintena. Care must be taken to avoid inadvertent injection of this medicinal product into a blood vessel. Following any confirmed or suspected accidental overdose/inadvertent intravenous&nbsp; administration, close observation of the patient is needed and if any potentially medically serious sign or symptom develops, monitoring, which should include continuous electrocardiographic monitoring, is required. The medical supervision and monitoring should continue until the patient recovers.</p><p>&nbsp;</p><p>A simulation of dose dumping showed that the predicted median aripiprazole concentration reaches a peak of 4500 ng/ml or approximately 9 times the upper therapeutic range. In case of dose dumping, aripiprazole concentrations are predicted to descend rapidly to the upper limit of the therapeutic window after approximately 3 days. By the 7th day, the median aripiprazole concentrations further decline to concentrations following an IM depot dose with no dose dumping. While overdose is less likely with parenteral than oral medicinal products, reference information for oral aripiprazole overdose is presented below.</p><p><em>&nbsp;</em></p><p><em>Signs and symptoms</em></p><p>In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260&nbsp;mg (41&nbsp;times highest recommended daily aripiprazole dose) with no fatalities. The potentially medically important signs and symptoms observed included lethargy, increased blood pressure, somnolence, tachycardia, nausea, vomiting and diarrhoea. In addition, reports of accidental overdose with aripiprazole alone (up to 195&nbsp;mg) in children have been received with no fatalities. The potentially medically serious signs and symptoms reported included somnolence, transient loss of consciousness and extrapyramidal symptoms.</p><p>&nbsp;</p><p><em>Management of overdose</em></p><p>Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms.</p><p>The possibility of multiple medicinal product involvement should be considered. Therefore, cardiovascular monitoring should be started immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.</p><p><em>&nbsp;</em></p><p><em>Haemodialysis</em></p><p>Although there is no information on the effect of haemodialysis in treating an overdose with aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pharmacotherapeutic group: Psycholeptics, other antipsychotics, ATC code: N05AX12</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>It has been proposed that aripiprazole&rsquo;s efficacy in schizophrenia is mediated through a combination of partial agonism at dopamine D2 and serotonin 5‑HT1A receptors and antagonism at serotonin 5‑HT2A receptors. Aripiprazole exhibited antagonist properties in animal models of dopaminergic hyperactivity and agonist properties of dopaminergic hypoactivity. Aripiprazole exhibits high binding affinity <em>in vitro</em> for dopamine D2 and D3, serotonin 5‑HT1A and 5‑HT2A receptors and has moderate affinity for dopamine D4, serotonin 5‑HT2C and 5‑HT7, alpha-1 adrenergic, and histamine H1 receptors. Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for cholinergic muscarinic receptors. Interaction with receptors other than dopamine and serotonin subtypes may explain some of the other clinical effects of aripiprazole.&nbsp;</p><p>&nbsp;</p><p>Aripiprazole oral doses ranging from 0.5 to 30&nbsp;mg administered once a day to healthy subjects for 2&nbsp;weeks produced a dose-dependent reduction in the binding of <sup>11</sup>C‑raclopride, a D2/D3 receptor ligand, to the caudate and putamen detected by positron emission tomography.</p><p>&nbsp;</p><p><u>Further information on clinical trials:</u></p><p>&nbsp;</p><p><em>Maintenance treatment of schizophrenia in adults </em></p><p>The efficacy of Abilify Maintena in the maintenance treatment of patients with schizophrenia was established in two randomised, double-blind trials.</p><p>&nbsp;</p><p>The first trial was a 38&nbsp;week, randomised, double-blind, active‑controlled trial designed to establish the efficacy, safety, and tolerability of this medicinal product administered as monthly injections compared to once daily oral aripiprazole tablets 10‑30&nbsp;mg as maintenance treatment in adult patients with schizophrenia. This trial consisted of a screening phase and 3&nbsp;treatment phases: Conversion Phase, Oral Stabilisation Phase, and Double-blind, Active-controlled Phase.</p><p>&nbsp;</p><p>Six-hundred and sixty two patients eligible for the 38‑week Double-Blind, Active-Controlled Phase were randomly assigned in a 2:2:1 ratio to double-blind treatment to one of 3 treatment groups: 1) Abilify Maintena 2) the stabilisation dose of oral aripiprazole 10‑30&nbsp;mg, or 3) aripiprazole Long-Acting Injectable&nbsp;50&nbsp;mg/25&nbsp;mg. The aripiprazole Long-Acting Injectable 50&nbsp;mg/25&nbsp;mg dose was included as a low dose aripiprazole group to test assay sensitivity for the non-inferiority design.</p><p>The results of analysis of the primary efficacy endpoint, the estimated proportion of patients experiencing impending relapse by end of Week&nbsp;26 of the Double-blind, Active-controlled Phase, showed that Abilify Maintena 400&nbsp;mg/300&nbsp;mg is non-inferior to aripiprazole oral tablets 10‑30&nbsp;mg.</p><p>The estimated relapse rate by end of Week&nbsp;26 was 7.12&nbsp;% in the Abilify Maintena group, and 7.76&nbsp;% in the oral aripiprazole tablets 10‑30&nbsp;mg group, a difference of ‑0.64&nbsp;%. The 95&nbsp;% CI (‑5.26, 3.99) for the difference in the estimated proportion of patients experiencing impending relapse by end of Week&nbsp;26 excluded the predefined non-inferiority margin, 11.5&nbsp;%. Therefore, Abilify Maintena is non-inferior to the aripiprazole oral tablets 10‑30&nbsp;mg formulation.</p><p>&nbsp;</p><p>The estimated proportion of patients experiencing impending relapse by end of Week&nbsp;26 for the Abilify Maintena group was 7.12&nbsp;%, which was statistically significantly lower than in the aripiprazole Long-Acting Injectable 50&nbsp;mg/25&nbsp;mg group (21.80&nbsp;%; p&nbsp;=&nbsp;0.0006). Thus, superiority of Abilify Maintena over the aripiprazole Long-Acting Injectable 50&nbsp;mg/25&nbsp;mg was established and the validity of the trial design was confirmed.</p><p>&nbsp;</p><p>The Kaplan-Meier curves of the time from randomisation to impending relapse during the 38‑week, double-blind treatment phase for Abilify Maintena, oral aripiprazole 10‑30&nbsp;mg group, and aripiprazole Long-Acting Injectable 50&nbsp;mg/25&nbsp;mg groups are shown in Figure&nbsp;1.</p><p>&nbsp;</p><p><strong>Figure&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier Product Limit Plot for Time to Exacerbation of Psychotic Symptoms/Impending Relapse</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Grafik_x0020_3207" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:398.5pt;height:249.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title="" croptop="3053f" cropbottom="2913f" cropright="11739f"/>
</v:shape><![endif]--><img width="531" height="333" alt="" src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>NOTE: ARIP IMD 400/300&nbsp;mg&nbsp;=&nbsp;Abilify Maintena;ARIP 10‑30&nbsp;mg&nbsp;=&nbsp;oral aripiprazole; ARIP IMD 50/25&nbsp;mg&nbsp;=&nbsp;Long-acting Injectable</p><p>&nbsp;</p><p>Further, the non-inferiority of Abilify Maintena compared to oral aripiprazole 10‑30&nbsp;mg is supported by the results of the analysis of Positive and Negative Syndrome Scale for Schizophrenia (PANSS).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PANSS Total Score &ndash; Change From Baseline to Week&nbsp;38-LOCF:<br />Randomised Efficacy Sample <sup>a, b</sup></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>PANSS Total Score &ndash; Change From Baseline to Week&nbsp;38-LOCF:</strong></p><p><strong>Randomised Efficacy Sample <sup>a, b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abilify Maintena 400&nbsp;mg/300&nbsp;mg</p><p>(n&nbsp;=&nbsp;263)</p></td><td style="vertical-align:top"><p>Oral aripiprazole</p><p>&nbsp;</p><p>10‑30&nbsp;mg/day</p><p>(n&nbsp;=&nbsp;266)</p></td><td style="vertical-align:top"><p>Aripiprazole Long-Acting Injectable 50&nbsp;mg/25&nbsp;mg</p><p>&nbsp;</p><p>(n&nbsp;=&nbsp;131)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean baseline (SD)</strong></p></td><td style="vertical-align:top"><p>57.9 (12.94)</p></td><td style="vertical-align:top"><p>56.6 (12.65)</p></td><td style="vertical-align:top"><p>56.1 (12.59)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean change (SD)</strong></p></td><td style="vertical-align:top"><p>‑1.8 (10.49)</p></td><td style="vertical-align:top"><p>0.7 (11.60)</p></td><td style="vertical-align:top"><p>3.2 (14.45)</p></td></tr><tr><td style="vertical-align:top"><p><strong>P-value</strong></p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>0.0272</p></td><td style="vertical-align:top"><p>0.0002</p></td></tr></tbody></table><p>a: &nbsp;&nbsp; Negative change in score indicates improvement.</p><p>b: &nbsp;&nbsp; Only patients having both baseline and at least one post baseline were included. P-values were derived from comparison for change from baseline within analysis of covariance model with treatment as term and baseline as covariate.</p><p>&nbsp;</p><p>The second trial was a 52‑week, randomised, withdrawal, double-blind, trial conducted in adult patients with a current diagnosis of schizophrenia. This trial consisted of a screening phase and 4 treatment phases: Conversion, Oral Stabilisation, Abilify Maintena Stabilisation, and Double-blind Placebo-controlled. Patients fulfilling the oral stabilisation requirement in the Oral Stabilisation Phase were assigned to receive, in a single-blind fashion, Abilify Maintena and began an Abilify Maintena Stabilisation Phase for a minimum of 12&nbsp;weeks and a maximum of 36&nbsp;weeks. Patients eligible for the Double-blind, Placebo-controlled Phase were randomly assigned in a 2:1 ratio to double-blind treatment with Abilify Maintena or placebo, respectively.</p><p>&nbsp;</p><p>The final efficacy analysis included 403 randomised patients and 80 exacerbations of psychotic symptoms/impending relapse events.</p><p>The study was terminated early because efficacy was demonstrated by the pre-specified interim analysis. The hazard ratio from the Cox proportional hazard model for the placebo to ABILIFY MAINTENA comparison was 5.029 (95&nbsp;% CI&nbsp;=&nbsp;3.154, 8.018); thus patients in the placebo group had a 5.03‑fold greater risk of experiencing impending relapse than patients in the ABILIFY MAINTENA group.&nbsp; These results support efficacy for ABILIFY MAINTENA over 52&nbsp;weeks of treatment.</p><p>&nbsp;</p><p>The Kaplan-Meier curves of the time from randomisation to impending relapse during the 52‑week, double-blind treatment phase for ABILIFY MAINTENA and placebo groups are shown in Figure&nbsp;2.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Figure&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier Product Limit Plot for Time to Exacerbation of Psychotic Symptoms/Impending Relapse</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_42" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:343pt;
 height:225.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="457" height="301" alt="" src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></p><p>&nbsp;</p><p>The percentage of patients meeting the impending relapse criteria was significantly lower (p&nbsp;&lt;&nbsp;0.0001) in the Abilify Maintena group (10.0&nbsp;%) than in the placebo group (39.6&nbsp;%).</p><p>&nbsp;</p><p>Further, the superiority of Abilify Maintena compared to placebo is supported by the results of the analysis of PANSS.</p><p>&nbsp;</p><p><strong>Table&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PANSS Total Score - Change From Baseline to Week&nbsp;52- LOCF: Randomised Efficacy Sample <sup>a</sup></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>PANSS Total Score - Change From Baseline to Week&nbsp;52- LOCF:</strong></p><p><strong>Randomised Efficacy Sample<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ABILIFY MAINTENA 400&nbsp;mg/300&nbsp;mg</p><p>(n&nbsp;=&nbsp;266)</p></td><td style="vertical-align:top"><p>Placebo<br />(n&nbsp;=&nbsp;134)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean baseline (SD)</strong></p></td><td style="vertical-align:top"><p>54.4 (11.96)</p></td><td style="vertical-align:top"><p>54.4 (11.59)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean change (SD)</strong></p></td><td style="vertical-align:top"><p>1.43 (10.82)</p></td><td style="vertical-align:top"><p>11.6 (15.21)</p></td></tr><tr><td style="vertical-align:top"><p><strong>P-value</strong></p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr></tbody></table><p>a: Only patients having both baseline and at least one post baseline were included. P-values were derived from comparison for change from baseline within analysis of covariance model with treatment as term and baseline as covariate.</p><p>&nbsp;</p><p><em>Prolactin</em></p><p>In the double-blind active-controlled phase of the 38‑week, trial, from baseline to last visit there was a mean decrease in prolactin levels in the Abilify Maintena group (&minus;0.33&nbsp;ng/ml) compared with a mean increase in the oral aripiprazole tablets 10‑30&nbsp;mg group (0.79&nbsp;ng/ml; p &lt;&nbsp;0.01). The incidence of Abilify Maintena patients with prolactin levels &gt;&nbsp;1 time the upper limit of normal range (ULN) at any assessment was 5.4&nbsp;% compared with 3.5&nbsp;% of the patients on oral aripiprazole tablets 10‑30&nbsp;mg. Male patients generally had a higher incidence than female patients in each treatment group.</p><p>&nbsp;</p><p>In the double-blind placebo-controlled phase of the 52‑week trial, from baseline to last visit there was a mean decrease in prolactin levels in the Abilify Maintena group (&minus;0.38&nbsp;ng/ml) compared with a mean increase in the placebo group (1.67&nbsp;ng/ml). The incidences of Abilify Maintena patients with prolactin levels &gt;&nbsp;1 time the upper limit of normal range (ULN) was 1.9&nbsp;% compared to 7.1&nbsp;% for placebo patients.</p><p>&nbsp;</p><p><em>Acute treatment of schizophrenia in adults</em></p><p>The efficacy of Abilify Maintena in acutely relapsed adult patients with schizophrenia was established in a short-term (12-week), randomised, double-blind, placebo-controlled trial (n&nbsp;=&nbsp;339).</p><p>The primary endpoint (change in PANSS total score from baseline to week&nbsp;10) showed superiority of Abilify Maintena (n&nbsp;=&nbsp;167) over placebo (n&nbsp;=&nbsp;172).</p><p>Similar to the PANSS Total Score, both the PANSS positive and negative subscale scores also showed an improvement (decrease) from baseline over time.</p><p>&nbsp;</p><p><strong>Table&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PANSS Total Score &ndash; Change from baseline to week&nbsp;10: Randomised efficacy sample</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>PANSS Total Score &ndash; Change from baseline to week&nbsp;10:</strong></p><p><strong>Randomised efficacy sample <sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><sup>&nbsp;</sup></strong></p></td><td style="vertical-align:top"><p><strong>Abilify Maintena</strong></p><p><strong>400&nbsp;mg/300&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong><sup>&nbsp;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean baseline (SD)</strong></p></td><td style="vertical-align:top"><p>102.4 (11.4)</p><p>n&nbsp;=&nbsp;162</p></td><td style="vertical-align:top"><p>103.4 (11.1)</p><p>n&nbsp;=&nbsp;167</p></td></tr><tr><td style="vertical-align:top"><p><strong>LS Mean change (SE)</strong></p></td><td style="vertical-align:top"><p>-26.8 (1.6)</p><p>n&nbsp;=&nbsp;99</p></td><td style="vertical-align:top"><p>-11.7 (1.6)</p><p>n&nbsp;=&nbsp;81</p></td></tr><tr><td style="vertical-align:top"><p><strong>P-value</strong></p></td><td style="vertical-align:top"><p>&lt; 0.0001</p></td><td style="vertical-align:top"><p><strong><sup>&nbsp;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Treatment difference<sup>b</sup> (95&nbsp;% CI)</strong></p></td><td style="vertical-align:top"><p>-15.1 (-19.4, -10.8)</p></td><td style="vertical-align:top"><p><strong><sup>&nbsp;</sup></strong></p></td></tr></tbody></table><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Data were analysed using a mixed model repeated measures (MMRM) approach. The analysis included only subjects who were &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; randomly assigned to treatment, given at least one injection, had baseline and at least one post-baseline efficacy assessment.</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Difference (Abilify Maintena minus placebo) in least squares mean change from baseline.</p><p>&nbsp;</p><p>Abilify Maintena also showed statistically significant improvement in symptoms represented by CGIS score change from baseline to week&nbsp;10.</p><p>&nbsp;</p><p>Personal and social functioning were evaluated using the Personal and Social Performance (PSP) scale. The PSP is a validated clinician-rated scale that measures personal and social functioning in four domains: socially useful activities (e.g. work and study), personal and social relationships, self-care, and disturbing and aggressive behaviours. There was a statistically significant treatment difference in favour of Abilify Maintena 400&nbsp;mg/300&nbsp;mg compared to placebo at week&nbsp;10 (+7.1, p&nbsp;&lt;&nbsp;0.0001, 95&nbsp;% CI: 4.1, 10.1 using an ANCOVA model (LOCF)).</p><p>&nbsp;</p><p>The safety profile was consistent with that known to Abilify Maintena. Nevertheless, there were differences from what has been observed with maintenance use in the treatment of schizophrenia. In a short-term (12-week), randomised, double-blind, placebo-controlled trial with Abilify Maintena 400&nbsp;mg/300&nbsp;mg treated subjects the symptoms which had at least twice the incidence of placebo were increased weight and akathisia. The incidence of weight gain of&nbsp;&ge;&nbsp;7&nbsp;% from baseline to last visit (week&nbsp;12) was 21.5&nbsp;% for Abilify Maintena compared with the placebo group 8.5&nbsp;%. Akathisia was the most frequently observed EPS symptom (Abilify Maintena 11.4&nbsp;% and placebo group 3.5&nbsp;%).</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Abilify Maintena in all subsets of the paediatric population in schizophrenia (see section&nbsp;4.2).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Aripiprazole absorption into the systemic circulation is slow and prolonged following Abilify Maintena administration due to low solubility of aripiprazole particles.</p><p>&nbsp;</p><p>The average absorption half-life of Abilify Maintena is 28 days. Absorption of aripiprazole from the IM depot formulation was complete relative to the IM standard (immediate-release) formulation. The dose adjusted C<sub>max</sub> values for the depot formulation were approximately 5% of C<sub>max</sub> from IM standard formulation.</p><p>&nbsp;</p><p>Following a single dose administration of Abilify Maintena in the deltoid and gluteal muscle, the extent of absorption (AUC) was similar for both injection sites, but the rate of absorption (C<sub>max</sub>) was higher following administration to the deltoid muscle.</p><p>&nbsp;</p><p>Following multiple intramuscular doses, the plasma concentrations of aripiprazole gradually rise to a maximum&nbsp;plasma concentration at a median t<sub>max </sub>of&nbsp;7&nbsp;days for the gluteal muscle and 4&nbsp;days for the deltoid muscle.</p><p>&nbsp;</p><p>Steady state concentrations for the typical subject were attained by the fourth dose for both sites of administration.</p><p>&nbsp;</p><p>Less than dose-proportional increases in aripiprazole and dehydro-aripiprazole concentrations and AUC parameters are observed after monthly Abilify Maintena injections of 300&nbsp;mg to 400 mg.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>Based on results from trials with oral administration of aripiprazole, aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9&nbsp;l/kg, indicating extensive extravascular distribution. At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater than 99&nbsp;% bound to serum proteins, binding primarily to albumin.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Aripiprazole is extensively metabolised by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on <em>in-vitro</em> studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal product moiety in systemic circulation. After multiple dose administration of Abilify Maintena, dehydro-aripiprazole, the active metabolite, represents about&nbsp; 29.1-32.5 % of aripiprazole AUC in plasma.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>After administration of multiple dose of 400&nbsp;mg or 300&nbsp;mg of Abilify Maintena, the mean aripiprazole terminal elimination half-life is respectively 46.5 and 29.9&nbsp;days presumably due to absorption rate-limited kinetics.</p><p>Following a single oral dose of [<sup>14</sup>C]-labelled aripiprazole, approximately 27&nbsp;% of the administered radioactivity was recovered in the urine and approximately 60&nbsp;% in the faeces. Less than 1&nbsp;% of unchanged aripiprazole was excreted in the urine and approximately 18&nbsp;% was recovered unchanged in the faeces.</p><p><u>&nbsp;</u></p><p><em>Pharmacokinetics in special patient groups</em></p><p>&nbsp;</p><p><u>CYP2D6 poor metabolisers</u></p><p>Based on population pharmacokinetic evaluation of Abilify Maintena, the total body clearance of aripiprazole was 3.71&nbsp;L/h in extensive metabolisers of CYP2D6 and approximately 1.88&nbsp;L/h (approximately 50&nbsp;% lower) in poor metabolisers of CYP2D6 (for dose recommendation, see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Elderly</u></p><p>After oral administration of aripiprazole, there are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects. Similarly, there was no detectable effect of age in a population pharmacokinetic analysis of Abilify Maintena in schizophrenia patients.</p><p><u>&nbsp;</u></p><p><u>Gender</u></p><p>After oral administration of aripiprazole, there are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects. Similarly, there was no clinically relevant effect of gender in a population pharmacokinetic analysis of Abilify Maintena in clinical trials in patients with schizophrenia.</p><p>&nbsp;</p><p><u>Smoking</u></p><p>Population pharmacokinetic evaluation of oral aripiprazole has revealed no evidence of clinically relevant effects from smoking on the pharmacokinetics of aripiprazole.</p><p>&nbsp;</p><p><u>Race </u></p><p>Population pharmacokinetic evaluation showed no evidence of race-related differences on the pharmacokinetics of aripiprazole.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>In a single-dose study with oral administration of aripiprazole, the pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to that in young healthy subjects.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>A single-dose study with oral administration of aripiprazole to subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3&nbsp;patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxicological profile for aripiprazole administered to experimental animals by intramuscular injection is generally similar to that seen following oral administration at comparable plasma levels. With intramuscular injection, however an inflammatory response was seen at the injection site, and consisted of granulomatous inflammation, foci (deposited drug), cellular infiltrates, oedema (swelling) and, in monkeys, fibrosis. These effects gradually resolved with discontinuation of dosing.</p><p>&nbsp;</p><p>Non-clinical safety data for orally administered aripiprazole revealed no special hazard for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, genotoxicity, and carcinogenic potential.</p><p>&nbsp;</p><p><em>Oral aripiprazole</em></p><p>For oral aripiprazole, toxicologically significant effects were observed only at doses or exposures that were sufficiently in excess of the maximum human dose or exposure, indicating that these effects were limited or of no relevance to clinical use. These included: dose-dependent adrenocortical toxicity in rats after 104&nbsp;weeks of oral administration at approximately 3 to 10&nbsp;times the mean steady-state AUC at the maximum recommended human dose and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at approximately 10&nbsp;times the mean steady-state AUC at the maximum recommended human dose. The highest non-tumorigenic exposure in female rats was approximately 7&nbsp;times the human exposure at the recommended dose.</p><p>&nbsp;</p><p>An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy-metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 to 125&nbsp;mg/kg/day or approximately16 to 81&nbsp;times the maximum recommended human dose based on mg/m<sup>2</sup>.</p><p>&nbsp;</p><p>However, the concentrations of the sulphate conjugates of hydroxy-aripiprazole in human bile at the highest dose proposed, 30&nbsp;mg per day, were no more than 6&nbsp;% of the bile concentrations found in the monkeys in the 39‑week study and are well below (6&nbsp;%) their limits of <em>in vitro</em> solubility.</p><p>&nbsp;</p><p>In repeat dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable to that observed in adult animals, and there was no evidence of neurotoxicity or adverse events on development.</p><p>&nbsp;</p><p>Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity studies.</p><p>Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in sub-therapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures approximately 3 and 11&nbsp;times the mean steady-state AUC at the maximum recommended clinical dose. Maternal toxicity occurred at doses similar to those eliciting developmental toxicity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder</u></p><p>Carmellose sodium</p><p>Mannitol</p><p>Sodium dihydrogen phosphate monohydrate</p><p>Sodium hydroxide</p><p>&nbsp;</p><p><u>Solvent</u></p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years

After reconstitution
Chemical and physical in-use stability has been demonstrated for 4 hours at 25°C. From a microbiological point of view, unless the method of opening/ reconstitution precludes the risk of microbial contamination, the product should be used immediately. 
If not used immediately, in-use storage times and conditions are the responsibility of user. Shake the vial vigorously for at least 60 seconds to re-suspend prior to injection. Do not store the reconstituted suspension in the syringe.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><br />Do not store above 30 &ordm;C.<br />Do not freeze.&nbsp;<br />For storage conditions after reconstitution of the medicinal product, see section 6.3.</p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not all pack sizes or kit types may be marketed</p><p><u>&nbsp;</u></p><p>400&nbsp;mg powder:</p><p>Type‑I glass vial stoppered with a laminated rubber stopper and sealed with a flip-off aluminium cap.</p><p>&nbsp;</p><p>Solvent:</p><p>2&nbsp;ml Type‑1 glass vial stoppered with a laminated rubber stopper and sealed with a flip-off aluminium cap.</p><p>&nbsp;</p><p>Each single pack containing one vial of powder, 2 ml vial of solvent.</p><p><u>&nbsp;</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><u>Step&nbsp;1: Preparation prior to reconstitution of the powder.</u></p><p>&nbsp;</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lay out and confirm that components listed below are provided:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abilify Maintena package leaflet and instructions for healthcare professionals</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vial of powder</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;ml vial of solvent</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Important:</strong> the solvent vial contains an overfill.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended needle for</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gluteal for administration is a 38&nbsp;mm (1.5&nbsp;inch), 22&nbsp;gauge hypodermic safety needle. For obese patients (Body mass index &gt; 28 kg/m2), a 51&nbsp;mm (2&nbsp;inch), 21&nbsp;gauge hypodermic safety needle should be used.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deltoid administration is a 25&nbsp;mm (1&nbsp;inch), 23&nbsp;gauge hypodermic safety needle. For obese patients, a 38&nbsp;mm (1.5&nbsp;inch), 22&nbsp;gauge hypodermic safety needle should be used.</p><p>&nbsp;</p><p><u>Step&nbsp;2: Reconstitution of the powder</u></p><p><strong>&nbsp;</strong></p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the solvent and powder vial caps and wipe the tops with a sterile alcohol swab.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Using a proper syringe, withdraw the pre-determined solvent volume from the vial of the solvent into the syringe.</p><p>400&nbsp;mg vial:</p><p>Add 1.9&nbsp;ml solvent to reconstitute the powder</p><p>A small amount of residual solvent will remain in the vial following withdrawal. Any excess should be discarded.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:38pt;height:99.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="" grayscale="t"/>
</v:shape><![endif]--><img width="51" height="133" alt="" src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>&nbsp;</p><p>&nbsp;</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slowly inject the solvent into the vial containing the powder.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_2" o:spid="_x0000_i1026"
 type="#_x0000_t75" style='width:42pt;height:106pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title="" grayscale="t"/>
</v:shape><![endif]--><img width="56" height="141" alt="" src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></p><p>&nbsp;</p><p>&nbsp;</p><p>d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Shake the vial vigorously for 30&nbsp;seconds until the suspension appears uniform</u>.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:61.5pt;height:78.5pt'>
 <v:imagedata src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
  o:title=""/>
</v:shape><![endif]--><img width="82" height="105" alt="" src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></p><p>&nbsp;</p><p>&nbsp;</p><p>e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visually inspect the reconstituted suspension for particulate matter and discolouration prior to administration. The reconstituted medicine is a white to off-white, fluid suspension. Do not use if reconstituted suspension contains particulate matter or any discolouration.</p><p>f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the injection is not performed immediately after reconstitution, keep the vial below 25&nbsp;&deg;C for up to 4&nbsp;hours and shake it vigorously for at least 60&nbsp;seconds to re-suspend prior to injection.</p><p>g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store the reconstituted suspension in the syringe.</p><p>&nbsp;</p><p><u>Step&nbsp;3: Preparation prior to injection</u></p><p>&nbsp;</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Determine the recommended volume for injection.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:288px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Abilify Maintena 400&nbsp;mg Vial</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dose</p></td><td style="vertical-align:top"><p>Volume to Inject</p></td></tr><tr><td style="vertical-align:top"><p>400&nbsp;mg</p></td><td style="vertical-align:top"><p>2.0&nbsp;ml</p></td></tr><tr><td style="vertical-align:top"><p>300&nbsp;mg</p></td><td style="vertical-align:top"><p>1.5&nbsp;ml</p></td></tr><tr><td style="vertical-align:top"><p>200&nbsp;mg</p></td><td style="vertical-align:top"><p>1.0&nbsp;ml</p></td></tr><tr><td style="vertical-align:top"><p>160&nbsp;mg</p></td><td style="vertical-align:top"><p>0.8&nbsp;ml</p></td></tr></tbody></table><p>&nbsp;</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wipe the top of the vial of the reconstituted suspension with a sterile alcohol swab.</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Using a proper syringe, slowly withdraw the recommended volume from the vial of the reconstitued suspension.</p><p><u>A small amount of excess product will remain in the vial.</u></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Grafik_x0020_16"
 o:spid="_x0000_i1028" type="#_x0000_t75" style='width:50.5pt;height:120.5pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image007.emz"
  o:title=""/>
</v:shape><![endif]--><img width="67" height="161" alt="" src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" /></p><p>&nbsp;</p><p><u>Step&nbsp;4: Injection procedure</u></p><p>&nbsp;</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Select a proper needlee depending on the injection site and patient&rsquo;s weight.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body type</strong></p></td><td style="vertical-align:top"><p><strong>Injection site</strong></p></td><td style="vertical-align:top"><p><strong>Needle size</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Non-obese</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Deltoid</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>25&nbsp;mm (1&nbsp;inch) 23&nbsp;gauge</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Gluteal</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>38&nbsp;mm (1.5&nbsp;inch) 22&nbsp;gauge</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Obese</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Deltoid</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>38&nbsp;mm (1.5&nbsp;inch) 22&nbsp;gauge</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Gluteal</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>51&nbsp;mm (2&nbsp;inch) 21&nbsp;gauge</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slowly inject the recommended volume as a single intramuscular injection into the gluteal or deltoid muscle. Do not massage the injection site. Care must be taken to avoid inadvertent injection into the blood vessel. Do not inject into an area with signs of inflammation, skin damage, lumps and/or bruises.</p><p>For deep intramuscular gluteal or deltoid injection only.</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:187pt;
   height:135.5pt'>
   <v:imagedata src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.emz"
    o:title="" cropright="32232f"/>
  </v:shape><![endif]--><img width="249" height="181" src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Grafik_x0020_6"
   o:spid="_x0000_i1026" type="#_x0000_t75" style='width:140.5pt;height:134.5pt;
   visibility:visible'>
   <v:imagedata src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image003.emz"
    o:title=""/>
  </v:shape><![endif]--><img width="187" height="179" src="file:///C:/Users/KHAS/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></p></td></tr><tr><td style="vertical-align:top"><p>deltoid</p></td><td style="vertical-align:top"><p>gluteal</p><p>&nbsp;</p></td></tr></tbody></table><p>Remember to rotate sites of injections between the two gluteal or deltoid muscles.</p><p>If initiating with the two injection start, inject into two different sites in two different muscles. DO NOT inject both injections concomitantly into the same deltoid or gluteal muscle. For known CYP2D6 poor metabolisers administer in either two separate deltoid muscles or one deltoid and one gluteal muscle. DO NOT inject into two gluteal muscles.</p><p>Look for signs or symptoms of inadvertent intravenous administration.</p><p>&nbsp;</p><p><u>Step&nbsp;5: Procedures after injection</u></p><p>&nbsp;</p><p>Dispose of the vials, needles, and syringe appropriately after injection.</p><p>The powder and solvent vials are for single-use only.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                H. Lundbeck A/S
Ottiliavej 9, 2500 Valby
Denmark

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>